PFIZER INC.

These results are supplied for informational purposes only.
Prescribing decisions should be made based on the approved package insert.

GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550

PROTOCOL NO.: A3921080

PROTOCOL TITLE: A Phase 3, Multi-site, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 and 1 Subcutaneous Dose of Etanercept in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Centers: This study was conducted at 112 study centers in 25 countries: Argentina (1 center), Austria (3 centers), Belgium (1 center), Bosnia and Herzegovina (1 center), Bulgaria (5 centers), Chile (4 centers), Colombia (5 centers), Croatia (3 centers), the Czech Republic (5 centers), Denmark (3 centers), France (15 centers), Germany (15 centers), Hong Kong (1 center), Hungary (5 centers), the Republic of Korea (3 centers), the Netherlands (4 centers), Poland (5 centers), the Russian Federation (10 centers), Singapore (2 centers), Slovakia (3 centers), Spain (6 centers), Sweden (5 centers), Switzerland (1 center), Turkey (4 centers) and the United Kingdom (UK; 2 centers).

Study Initiation Date and Final Completion Date: 29 November 2010 to 29 January 2013

Phase of Development: Phase 3

Study Objectives:

Primary Objectives:

- To compare the efficacy of tofacitinib (5 mg twice daily [BID] and 10 mg BID) versus etanercept (50 mg twice weekly [BIW]) and placebo for the reduction in severity of plaque psoriasis after 12 weeks of treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

  Efficacy was measured by:

  - The Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to Baseline;

  - The Physician's Global Assessment (PGA) response, ie, the proportion of subjects achieving a PGA of "clear" or "almost clear";

- To evaluate the safety and tolerability of tofacitinib (5 mg BID and 10 mg BID) over 12 weeks of treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Secondary Objectives:

- To compare the efficacy of tofacitinib (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis at various time points during 12 weeks of treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy;

- To evaluate the effects on patient reported outcome (PRO) measures during 12 weeks of treatment with tofacitinib (5 mg BID and 10 mg BID) versus placebo at various time points in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

METHODS

Study Design: This was a Phase 3, multi-site, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study of the efficacy and safety of 2 oral doses of tofacitinib (5 mg BID and 10 mg BID) and 1 subcutaneous (SC) dose of etanercept (50 mg BIW) in subjects with moderate to severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy. Subjects were randomized in a 3:3:3:1 ratio to 1 of 4 parallel treatment groups (tofacitinib 5 mg BID; tofacitinib 10 mg BID; etanercept 50 mg BIW; placebo). Randomization of subjects to treatment was conducted at the country level and stratification was based on previous failed experience with systemic therapies into 2 strata: 1) inadequate response to, intolerance to, or contraindication to <3 systemic therapies or 2) inadequate response to, intolerance to, or contraindication to ≥3 systemic therapies. Systemic therapies included cyclosporine, methotrexate, acitretin, psoralen plus ultraviolet A light, alefacept, adalimumab, infliximab, and ustekinumab. Subjects previously exposed to etanercept or efalizumab were not eligible for study participation. The schedule of activities is summarized in Table 1.

Table 1 Schedule of Activities

Protocol Activity[a]	Screening			Visit 1 Baseline (D1)	Visit 2 Week 2 (D15)	Visit 3 Week 4 (D29)	Visit 4 Week 8 (D57)	Visit 5 ET/EOS)[a] Week 12 (D85) Baseline	Follow-Up (EOS)[a] Week 14-16 (D99 113)
	If >4 Week Washout Required	Within	If >4 Week Washout Required						
Informed consent[b]	X	X							
Register for subject identification number[b]	X	X							
Psoriasis diagnosis, medical history[c]	X	X							
Current/prior medications[d,h]	X	X							
Complete physical examination	X	X		X				X	X
Targeted physical examination[e]					X	X	X		
Vital signs, temperature		X		X	X	X	X	X	X
Weight, waist and hips circumference		X		X				X	
12-lead ECG	X	X		X				X	
QFT-G (or Mantoux/PPD Skin Test)[f]	X	X							
Chest radiographs[f]	X	X							
Laboratory Testing									
Hematology[g]	X	X		X		X	X	X	X
HbA1c				X				X	
Serum chemistry (fasting)[h,i]	X	X		X		X	X	X	X
Lipid panel (fasting)[h,j]	X	X		X		X	X	X	X
Lipoproteins (fasting)[h,k]				X		X		X	
Urinalysis, urine pregnancy test (β-hCG)[l]	X	X		X	X[l]	X	X	X	X
hsCRP	X	X		X		X		X	
HBsAg, HCV Ab, HIV serology	X	X							
EBC serology (French sites only)	X	X							
Clinical Evaluation of Psoriasis									
PASI and BSA			X	X	X	X	X	X	X
PGA			X	X	X	X	X	X	X

Table 1 Schedule of Activities

Protocol Activity[a]	Screening			Visit 1 Baseline (D1)	Visit 2 Week 2 (D15)	Visit 3 Week 4 (D29)	Visit 4 Week 8 (D57)	Visit 5 ET/EOS)[a] Week 12 (D85) Baseline	Follow-Up (EOS)[a] Week 14-16 (D99 113)
	If >4 Week Washout Required	Within	If >4 Week Washout Required						
Plaque lesion photography[m]				X				X	
Patient-Reported Outcomes									
ISI[n]		X-X		X X	X	X	X	X	X
DLQI				X		X		X	
SF-36 (version 2, acute)				X				X	
PtGA				X	X	X	X	X	
PSSM								X	
EQ-5D				X				X	
Ps-HCRU[o]				X				X	
PQOL-12				X				X	
Other Protocol Activities									
Randomization				X					
Review of concomitant medications				X	X	X	X	X	X
AE reporting				X	X	X	X	X	X
Endpoint assessment of AEs[p]				X	X	X	X	X	X
Study drug dispensing/in-clinic dosing				X	X	X	X		
Regimen adherence review/drug accountability					X	X	X	X	
Topical emollient dispensing, as needed	X	X	X	X	X	X	X	X	

AE = adverse event, ALT = alanine aminotransferase, AST = aspartate aminotransferase, β-hCG = beta-human chorionic gonadotrophin, BSA = body surface area, CHD = coronary heart disease, CO_2 = carbonCPK = creatine phosphokinase, CRF = case report form, CV-SEAC = Cardiovascular Safety Endpoint Adjudication Committee, D = day, DLQI = Dermatology Life Quality Index, EBC = Epstein-Barr virus, ECG = electrocardiogram, EOS = end of study, EQ-5D = EuroQol 5 Dimensions, ET = early termination, GGT = gamma-glutamyl transferase, HbA1c = hemoglobin A1c, HBsAg = hepatitis B surface antigen, HCV Ab = hepatitis C antibody, HDL-C = high density lipoprotein cholesterol, HEENT = head, eyes, ears, nose and throat, HIV = human immunodeficiency virus, hsCRP = high sensitivity C-reactive protein, ISI = Itch Severity Item, LDL-C = low density lipoprotein cholesterol, PASI = Psoriasis Area and Severity Index, PGA = Physician's Global Assessment, PPD = purified protein derivative, PQOL-12= Psoriasis Quality of Life 12, Ps-HCRU = Psoriasis Health Care Resource Utilization Questionnaire, PSSM = Patient Satisfaction with Study Medication, PtGA = Patient Global Assessment, QFT-G = QuantiFERON TB Gold, RBC = red blood cell, SF-36 = Short Form 36, TB = tuberculosis, WBC = white blood cell.

a. Screening procedures were performed/confirmed within 4 weeks prior to the Baseline/Day 1 Visit, and were performed over >1 visit as necessary. For subjects requiring a washout >4 weeks in duration, a first Screening Visit was conducted to determine if the subject was initially eligible for the study and,

Table 1 Schedule of Activities

Protocol Activity[a]	Screening			Visit 1 Baseline (D1)	Visit 2 Week 2 (D15)	Visit 3 Week 4 (D29)	Visit 4 Week 8 (D57)	Visit 5 ET/EOS)[a] Week 12 (D85) Baseline	Follow-Up (EOS)[a] Week 14-16 (D99 113)
	If >4 Week Washout Required	Within	If >4 Week Washout Required						

therefore, appropriate to be washed out of the current treatment regimen. These subjects could return for a subsequent Screening Visit within 4 weeks prior to Baseline/Day 1, at which time all screening procedures were repeated.
The clinical evaluations of psoriasis at Screening (PASI, BSA, PGA) had an additional requirement to be performed no later than 2 weeks prior to the Baseline/Day 1 Visit; ie, between 4 to 2 weeks prior to the Baseline/Day 1 Visit.
There was a fasting requirement (9 hours) at Screening (for fasting lipid panel and fasting glucose).
All visits: Sites attempted to schedule each subject's visits to occur in the morning (prior to the subject's morning dose) and at the same time of day for that subject.
Visit windows: Screening = +3 day window; Visit 1 (Baseline/Day 1) = no window; all other post-Baseline visits = ±3 day window. Visit 1 (Baseline/Day 1) became the reference date by which subsequent visits were scheduled.
ET visit: If a subject discontinued from the study early, final study procedures were completed as described for Visit 5/Week 12.
EOS visit:

- If a subject transferred to the long-term, open-label safety study, the EOS visit for this study was Visit 5/Week 12.
- If a subject did not transfer to the long-term, open-label safety study and study drug was taken within the 2 weeks prior to Visit 5/Week 12, an off-treatment Follow-up/EOS Visit was conducted at the Follow-up Visit/Week 14-16 (2-4 weeks after Visit 5/Week 12).
- If a subject did not transfer to the long-term, open-label safety study and study drug was not taken within the 2 weeks prior to Visit 5/Week 12, an additional off-treatment Follow-up/EOS Visit was conducted at the discretion of the Investigator, ie, at the Follow-up Visit/Week 14-16 (2-4 weeks after Visit 5/Week 12).

b. Subjects taking prohibited medications that required a washout period that extended beyond the Screening period duration. For these subjects, a first Screening Visit occurred to obtain written informed consent and determine eligibility criteria were met prior to initiation of the washout period. In such cases, informed consent and registration for a subject identification number did not need to be repeated at the subsequent Screening Visit.
c. Medical history included targeted collection of details on plaque psoriasis, nail psoriasis, any prior rheumatologist confirmed diagnosis of psoriatic arthritis or rheumatoid arthritis, plaque psoriasis co-morbidities, cardiovascular risk factors, and any history of liver biopsy. Smoking status including passive smoking, average weekly alcohol consumption, and family history of premature CHD was also collected.
d. The CRF categorized collection of current/prior medications including details on use of (a) previous therapies for psoriasis and response outcome, (b) antihypertensive medications, (c) antidiabetic medications, and (d) lipid lowering medications.
e. Complete physical examination included general appearance, skin, HEENT, heart, lungs, abdomen, lower extremities (peripheral edema), neurologic and lymph nodes. Height was measured at the Screening within 4 weeks of Baseline/Day 1 only. Targeted physical examination consisted of skin, heart, lungs, abdomen, lower extremities (peripheral edema), and lymph nodes.
f. QFT-G (or Mantoux/PPD tuberculin skin test and chest radiographs were performed unless previously done within 3 months of a given Screening Visit and results documented prior to randomization. QFT-G did not need to be performed if a subject had previously received a documented adequate course of therapy for either latent or active TB infection. Mantoux/PPD tuberculin skin testing, if needed, required an additional visit to the clinic to read test results. Chest radiographs, if needed, required a non-study visit to a different location.

Table 1 Schedule of Activities

Protocol Activity[a]	Screening			Visit 1 Baseline (D1)	Visit 2 Week 2 (D15)	Visit 3 Week 4 (D29)	Visit 4 Week 8 (D57)	Visit 5 ET/EOS)[a] Week 12 (D85) Baseline	Follow-Up (EOS)[a] Week 14-16 (D99 113)
	If >4 Week Washout Required	Within	If >4 Week Washout Required						

g. Hematology included WBC count/differential; hemoglobin; hematocrit; RBC count, morphology, and indices; and reticulocyte and platelet counts. All hematology tests were performed by central laboratory.

h. There was a fasting requirement (9 hours) for serum chemistry (fasting glucose), lipid panel, and lipoproteins. The blood draws for laboratories requiring a fasting state were taken up to 48 hours prior to the Baseline/Day 1 Visit and up to 48 hours prior to or following all other visits, as necessary to ensure samples were collected in a fasting state.
Subjects took prescribed permitted oral concomitant medication, as needed, prior to study visits, if possible to administer with water only. Prescribed permitted oral concomitant medication that was taken with food or after meals was not taken until after fasting visit procedures (laboratory test sample collection, vital signs and weight measurement, and ECG recording) had been completed.
The time of day for study visits was considered in the context of specific underlying medical conditions (eg, diabetes mellitus) and other requirements (eg, fasting, administration of prescribed permitted concomitant medication). Subjects who had specific underlying medical conditions (eg, diabetes mellitus) received additional instructions regarding the fasting requirement and the timing of concomitant medication administration (eg, insulin) on study visit days, if required.

i. Serum Chemistry (fasting) includes urea nitrogen, creatinine, glucose (fasting), calcium, sodium, potassium, bicarbonate or total CO_2, chloride, total protein, total bilirubin, direct bilirubin, indirect bilirubin, ALT, AST, alkaline phosphatase, GGT, albumin, lactate dehydrogenase and CPK. All serum chemistry tests were performed by central laboratory.

j. Lipid panel (fasting) included total cholesterol, LDL-C (if triglycerides >400 mg/dL, LDL-C was determined by direct measurement), HDL-C, and triglycerides. All lipid panel tests were performed by central laboratory.

k. Lipoproteins (fasting) included apolipoproteins A1 and B as well as measurements of other lipoproteins, particle number, and particle size.
Lipoprotein analyses were held and conducted in batches at a later time to reduce inter-assay variability.

l. Urinalysis included specific gravity, pH, protein, glucose, ketones, nitrites, blood, and leukocyte esterase. If urinalysis was positive for blood, nitrites, leukocyte esterase, and/or protein, a microscopic analysis was performed. If urinalysis was positive for nitrites and/or leukocyte esterase or if clinically indicated, a urine culture was performed. All urinalysis was performed by central laboratory.
Urine pregnancy testing (β-hCG) was required only for women of childbearing potential; testing was repeated more frequently if required by local practices, if a menstrual cycle was missed, or if potential pregnancy was otherwise suspected. Urine pregnancy testing was performed (using methodology with a testing sensitivity of at least 25 mIU/mL) at the study site using test kits supplied by central laboratory.
At the Visit 2/Week 2, urinalysis was not required; only urine pregnancy testing was performed (if applicable).

m. Plaque lesion photography (half body or regional views) was performed only at participating study sites.

n. ISI was assessed daily starting 1 week prior to the Baseline/Day 1 Visit and daily between the Baseline/Day 1 Visit and Visit 2/Week 2. Subjects were provided with an ISI diary at the Screening Visit within 4 weeks of Baseline/Day 1 which was completed at home throughout the time frame noted above. During the 1 week prior to the Baseline/Day 1 Visit, subjects completed the ISI in their diary in the evening. Between the Baseline/Day 1 Visit and Visit 2/Week 2, subjects completed the ISI in their diary at the same time as they took their evening dose of study drug(s). The ISI was also completed during specified study visits.

Table 1 Schedule of Activities

Protocol Activity[a]	Screening			Visit 1 Baseline (D1)	Visit 2 Week 2 (D15)	Visit 3 Week 4 (D29)	Visit 4 Week 8 (D57)	Visit 5 ET/EOS)[a] Week 12 (D85) Baseline	Follow-Up (EOS)[a] Week 14-16 (D99 113)
	If >4 Week Washout Required	Within	If >4 Week Washout Required						

o. The Ps-HCRU was administered at the specified study visits to all subjects. Additionally, the Ps-HCRU was included in the subject dosing diary. Each day when taking their evening dose of study medication, subjects answered if they saw a healthcare professional or if their work was impacted by their psoriasis that day. If subjects answered "yes" they were asked to complete a copy of the Ps-HCRU contained in the dosing diary.

p. Specific cardiovascular events were submitted to the CV-SEAC for adjudication. Biopsies collected for potential malignancy events were submitted to the central laboratory for pathologist over read.

Number of Subjects (Planned and Analyzed): A total of approximately 1100 subjects were planned to be enrolled in the study. A total of 1454 subjects were screened for entry into the study and 1106 subjects were randomized to treatment. Of these, 1101 subjects were randomized and received at least 1 dose of study medication (329 subjects in the tofacitinib 5 mg BID group; 330 subjects in the tofacitinib 10 mg BID group; 335 subjects in the etanercept 50 mg BIW group; and 107 subjects in the placebo group).

Diagnosis and Main Criteria for Inclusion: Eligible subjects were at least 18 years of age, willing and able to sign consent and comply with scheduled visits and study procedures, with a diagnosis of plaque-type psoriasis (psoriasis vulgaris) covering at least 10% of total body surface area (BSA), a PASI score of ≥12 and a PGA score of 3 or 4 at Baseline, and considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis. Subjects with non-plaque or drug-induced forms of psoriasis, who could not discontinue current systemic and/or topical therapies for the treatment of psoriasis, who could not discontinue phototherapy, or who had any uncontrolled significant medical condition were excluded from the study.

Study Treatment: Tofacitinib (5 mg BID and 10 mg BID) or placebo was taken orally BID (approximately every 12 hours) and etanercept (50 mg BIW) or placebo was injected SC BIW (approximately every third or fourth day). Tofacitinib was provided as 5 mg tablets with corresponding matching placebo. Comparator study drug, etanercept, was provided as 1.0 mL prefilled syringes with corresponding matching placebo. If a subject missed taking a dose of study drug tablets at the typical dosing time, the dose was taken within 6 hours of the typical dosing time. If more than 6 hours past the typical dosing time, the dose was skipped and dosing resumed at the next scheduled dosing time.

Efficacy Endpoints:

Primary:

- PASI75 response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to Baseline, at Week 12.
- PGA response, ie, the proportion of subjects achieving a PGA of "clear" or "almost clear", at Week 12.

Secondary:

- PASI75 response at Weeks 2, 4, and 8.
- The percent change from Baseline in PASI at various time points through Week 12.
- Proportion of subjects achieving at least a 50% and 90% reduction in PASI relative to Baseline (PASI50 and PASI90, respectively) at various time points through Week 12.
- Time to PASI50 and PASI75 responses.

- Proportion of subjects with a PASI score ≥125% of the Baseline PASI score at various time points through Week 12.
- Actual and change from Baseline in PASI and PASI component scores at various time points through Week 12.
- PGA response at Weeks 2, 4, and 8.
- Proportion of subjects in each PGA category at various time points through Week 12.
- The actual BSA and percent change from Baseline in BSA at various time points through Week 12.
- Actual and change from Baseline in the Itch Severity Item (ISI) score at various time points through Week 12.
- Actual and change from Baseline on the Dermatology Life Quality Index (DLQI) score at various time points through Week 12.
- Other PRO measures to be assessed at various time points through Week 12, including:
    - Short Form-36 (version 2, acute) (SF-36).
    - Patient Global Assessment of Psoriasis (PtGA).
    - Patient Satisfaction with Study Medication (PSSM).
    - EuroQol 5 Dimensions (EQ-5D).
    - Psoriasis Health Care Resource Utilization Questionnaire (Ps-HCRU).
    - Psoriasis Quality of Life–12 (PQOL-12).

Safety Endpoints:

- Incidence and severity of adverse events (AEs) over 12 weeks of treatment.
- Incidence of clinical laboratory abnormalities and change from Baseline in clinical laboratory values over 12 weeks of treatment.
- Incidence of clinically significant changes in physical examination from Baseline over 12 weeks of treatment.
- Incidence of vital sign (blood pressure and heart rate) abnormalities and change from Baseline in vital sign measures over 12 weeks of treatment.

- Incidence of electrocardiogram (ECG) abnormalities and change from Baseline in ECG measures over 12 weeks of treatment.
- Summary of adjudicated cardiovascular endpoints.
- Summary of central laboratory pathologist over-read malignancy events.

Statistical Methods: The primary analysis population was the full analysis set (FAS), which included all subjects who were randomized to the study and received at least 1 dose of the randomized investigational drug (tofacitinib, etanercept, or placebo). The per protocol (PP) analysis set was a subset of subjects from FAS. FAS subjects who had a protocol deviation thought to affect the efficacy analysis were excluded from the PP efficacy analysis. The safety analysis set was defined as those subjects who received at least 1 dose of the study drug (tofacitinib, etanercept or placebo).

One of the primary objectives was to establish that at least 1 dose of tofacitinib (5 mg and 10 mg BID) was non-inferior to etanercept 50 mg BIW within the 15% non-inferiority margin for 2 primary endpoints (PASI75 response and PGA response of "clear" or "almost clear" at Week 12). Other objectives included establishing the superiority of 2 doses (10 mg BID and 5 mg BID) of tofacitinib to placebo, as well as to etanercept 50 mg BIW for PASI75 and PGA responses at Week 12.

In order to preserve the Type 1 error, a gate-keeping approach was used to assess each objective's endpoint at each dose sequentially, where statistical significance could be claimed for a given endpoint at a given dose only if the prior step in the sequence met the requirements for significance. For each comparison, the significance level (α) was set at 0.05 (2-sided) or equivalently at 0.025 (1-sided). This gate-keeping approach strongly protects the family-wise Type 1 error rate at the 0.05 (2-sided) level.

RESULTS

Subject Disposition and Demography:

Of a total of 1101 randomized and treated subjects (968 subjects [87.9%]) were randomized into the stratum of <3 systemic therapies: 283 subjects (86.0%) in the tofacitinib 5 mg BID group; 293 subjects (88.8%) in the tofacitinib 10 mg BID group; 300 subjects (89.6%) in the etanercept 50 mg BIW group; and 92 subjects (86.0%) in the placebo group. Subject disposition is summarized in Table 2.

Table 2 Subject Disposition

	Tofacitinib		Etanercept	Placebo	Total
	5 mg BID n (%)	10 mg BID n (%)	50 mg BIW n (%)	n (%)	n (%)
Screened (N=1454)					
Randomized (N)	330	332	336	108	1106
Safety analysis set[a]	329 (100)	330 (100)	335 (100)	107 (100)	1101 (100)
FAS[b]	329 (100)	330 (100)	335 (100)	107 (100)	1101 (100)
PP analysis set[c]	313 (95.1)	317 (96.1)	322 (96.1)	101 (94.4)	1053 (95.6)
Completed	306 (93.0)	306 (92.7)	313 (93.4)	95 (88.8)	1020 (92.6)
Discontinued from study[a]	23 (7.0)	24 (7.3)	22 (6.6)	12 (11.2)	81 (7.4)
Primary reason:					
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Adverse event	3 (0.9)	11 (3.3)	12 (3.6)	4 (3.7)	30 (2.7)
Related to study drug	2 (0.6)	8 (2.4)	10 (3.0)	4 (3.7)	24 (2.2)
Not related to study drug	1 (0.3)	3 (0.9)	2 (0.6)	0 (0.0)	6 (0.5)
Insufficient clinical response	5 (1.5)	2 (0.6)	2 (0.6)	3 (2.8)	12 (1.1)
Lost to follow-up	1 (0.3)	2 (0.6)	2 (0.6)	2 (1.9)	7 (0.6)
Subject no longer willing to participate in study	6 (1.8)	4 (1.2)	2 (0.6)	2 (1.9)	14 (1.3)
Other[d]	8 (2.4)	5 (1.5)	4 (1.2)	1 (0.9)	18 (1.6)

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PP = Per Protocol.

a. Safety Analysis Set - All subjects who received at least 1 dose of study drug.
b. FAS - All subjects who were randomized and received at least 1 dose of the randomized study drug.
c. PP Analysis Set - All FAS subjects who did not have any major protocol violations during the study. All protocol deviations were assessed by the team for potential impact on efficacy prior to unblinding the study.
d. Included all the reasons not specified above.

A summary of demographic and Baseline characteristics is presented in Table 3. The majority of the treated subjects were male (70.7%) and White (86.8%). The mean age was 44.0 years (median: 44.0 years, range: 18 years to 75 years). The mean weight of subjects was 84.1 kg (median: 82.9 kg, range 36.3 kg to 168.0 kg), and mean body mass index was 28.5 kg/m^2 (median: 28.0 kg/m^2, range: 24.9 kg/m^2 to 31.6 kg/m^2). Demographic characteristics were similar between treatment groups.

Table 3 Demographic Characteristics

	Tofacitinib				Etanercept 50 mg BIW		Placebo		Total	
	5 mg BID		10 mg BID							
	Male (N=236, 71.7%)	Female (N=93, 28.3%)	Male (N=238, 72.1%)	Female (N=92, 27.9%)	Male (N=233, 69.6%)	Female (N=102, 30.4%)	Male (N=71, 66.4%)	Female (N=36, 33.6%)	Male (N=778, 70.7%)	Female (N=323, 29.3%)
Age (years),										
n	236	93	238	92	233	102	71	36	778	323
Mean (SD)	44.2 (11.8)	44.8 (12.9)	43.3 (11.8)	44.5 (14.5)	43.1 (11.4)	43.7 (13.8)	45.7 (13.7)	46.9 (12.9)	43.7 (11.9)	44.6 (13.6)
Age category (years), n (%)										
18 to <45	125 (53.0)	43 (46.2)	124 (52.1)	43 (46.7)	133 (57.1)	47 (46.1)	32 (45.1)	17 (47.2)	414 (53.2)	150 (46.4)
45 to <65	98 (41.5)	46 (49.5)	107 (45.0)	39 (42.4)	93 (39.9)	49 (48.0)	33 (46.5)	17 (47.2)	331 (42.5)	151 (46.7)
≥65	13 (5.5)	4 (4.3)	7 (2.9)	10 (10.9)	7 (3.0)	6 (5.9)	6 (8.5)	2 (5.6)	33 (4.2)	22 (6.8)
Race, n (%)										
White	206 (87.3)	83 (89.2)	201 (84.5)	84 (91.3)	200 (85.8)	92 (90.2)	58 (81.7)	32 (88.9)	665 (85.5)	291 (90.1)
Black	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.1)	0 (0.0)
Asian	13 (5.5)	3 (3.2)	15 (6.3)	2 (2.2)	15 (6.4)	5 (4.9)	6 (8.5)	1 (2.8)	49 (6.3)	11 (3.4)
Other	16 (6.8)	7 (7.5)	20 (8.4)	6 (6.5)	17 (7.3)	5 (4.9)	5 (7.0)	3 (8.3)	58 (7.5)	21 (6.5)
Ethnicity, n (%)										
Hispanic/Latino	51 (21.6)	32 (34.4)	65 (27.3)	19 (20.7)	61 (26.2)	26 (25.5)	16 (22.5)	15 (41.7)	193 (24.8)	92 (28.5)
Not Hispanic/Latino	184 (78.0)	61 (65.6)	172 (72.3)	73 (79.3)	171 (73.4)	76 (74.5)	53 (74.6)	21 (58.3)	580 (74.6)	231 (71.5)
Weight (kg)										
Mean (SD)	88.4 (18.0)	74.1 (15.1)	88.0 (17.8)	76.1 (18.5)	87.2 (15.9)	74.7 (16.9)	86.9 (16.5)	76.8 (16.9)	87.8 (17.2)	75.2 (16.8)
Height (cm)										
Mean (SD)	175.7 (8.3)	160.2 (6.7)	175.3 (7.4)	162.6 (7.0)	175.5 (7.7)	162.0 (6.1)	175.5 (8.2)	162.4 (6.2)	175.5 (7.8)	161.7 (6.6)
BMI (kg/m^2)										
Mean (SD)	28.5 (5.1)	28.9 (5.8)	28.6 (5.3)	28.8 (6.9)	28.3 (4.8)	28.4 (6.0)	28.2 (4.6)	29.2 (7.0)	28.4 (5.0)	28.7 (6.3)
BMI category (kg/m^2), n (%)										
<18.5	2 (0.8)	0 (0.0)	1 (0.4)	1 (1.1)	2 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	5 (0.6)	1 (0.3)
18.5 to <25	52 (22.0)	21 (22.6)	56 (23.5)	26 (28.3)	58 (24.9)	36 (35.3)	14 (19.7)	11 (30.6)	180 (23.1)	94 (29.1)
25 to <30	107 (45.3)	38 (40.9)	94 (39.5)	29 (31.5)	95 (40.8)	25 (24.5)	36 (50.7)	11 (30.6)	332 (42.7)	103 (31.9)
30 to <40	68 (28.8)	30 (32.3)	79 (33.2)	31 (33.7)	73 (31.3)	36 (35.3)	20 (28.2)	11 (30.6)	240 (30.8)	108 (33.4)
≥40	6 (2.5)	4 (4.3)	8 (3.4)	5 (5.4)	5 (2.1)	5 (4.9)	1 (1.4)	3 (8.3)	20 (2.6)	17 (5.3)

BMI is defined as weight/(height x 0.01)^2.
BID = twice daily, BIW = twice weekly, BMI = body mass index, N = number of subjects, n = number of subjects meeting prespecified criteria, SD = standard deviation.

Primary Endpoint Results:

A summary of the proportion of subjects achieving PASI75 response and a PGA response of "clear" or "almost clear" at Week 12 is presented in Table 4.

The proportion of subjects achieving PASI75 response at Week 12 (FAS, non-responder imputation [NRI]) was similar for those subjects in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups, and higher compared to those subjects in the tofacitinib 5 mg BID group; all active groups had higher rates of PASI75 response at Week 12 (FAS, NRI) as compared to the placebo group.

The proportion of subjects achieving a PGA response of "clear" or "almost clear" at Week 12 (FAS, NRI) was also similar for those subjects in the tofacitinib 10 mg BID and etanercept BIW groups, and higher compared to those subjects in the tofacitinib5 mg BID group; all active treatment groups had higher rates of PGA response of "clear" or "almost clear" at Week 12 (FAS, NRI) as compared to the placebo group.

Non-inferiority of tofacitinib 10 mg BID versus etanercept 50 mg BIW was concluded given that the lower bounds of the 95% confidence interval (LCI) of the difference between the percentage of responders receiving tofacitinib 10 mg BID and etanercept 50 mg BIW for both PASI75 response and PGA responses of "clear" or "almost clear" at Week 12 were >-15%.

Superiority of tofacitinib 10 mg BID versus placebo for PASI75 and PGA responses of "clear" or "almost clear" at Week 12 was concluded as the LCIs of the differences in the percentage of responders were >0.

For the comparison of tofacitinib 5 mg BID versus etanercept for PASI75 at Week 12, non-inferiority was not met as the 95% LCIs for the difference in PASI75 response was <-15% (Difference: -19.29, 95% CI [-26.75, -11.83]). The 95% LCI of the difference between tofacitinib 5 mg BID and etanercept 50 mg BIW for a PGA response of "clear" or "almost clear" was <-15% (Difference: -19.16, 95% CI [-26.55, -11.76]). However, the 95% LCIs of the differences between tofacitinib 5 mg BID and placebo were >0 for both PASI75 (Difference: 33.91, 95% CI [27.06, 40.76]) and PGA responses of "clear" or "almost clear" at Week 12 (Difference: 32.16, 95% CI [23.51, 40.81]) (Table 4).

As the non-inferiority of tofacitinib 5 mg BID versus etanercept was not met, the superiority of tofacitinib 5 mg BID to placebo could not be formally tested according to the pre-specified testing decision rule, even though the LCI of 95% was >0 for both primary endpoints.

Table 4 Proportion of Subjects Achieving PASI75 Response and PGA Response of "Clear" or "Almost Clear" at Week 12 (FAS, NRI)

	Treatment	Response			Difference From Placebo (Active - Placebo)				Difference From Etanercept (Active - Etanercept)			
		N	n (%)	SE	Diff	SE	95% CI	p-value	Diff	SE	95% CI	p-value
PASI75 Week 12	Tofacitinib 5 mg BID	329	130 (39.51)	2.70	33.91	3.49	27.06, 40.76	<0.0001	-19.29	3.81	-26.75, -11.83	<0.0001
	Tofacitinib 10 mg BID	330	210 (63.64)	2.65	58.03	3.46	51.25, 64.81	<0.0001	4.83	3.77	-2.57, 12.23	0.2006
	Etanercept 50 mg BIW	335	197 (58.81)	2.69	53.20	3.49	46.36, 60.04	<0.0001				
	Placebo	107	6 (5.61)	2.22								
PGA Week 12	Tofacitinib 5 mg BID	329	155 (47.11)	2.75	32.16	4.41	23.51, 40.81	<0.0001	-19.16	3.77	-26.55, -11.76	<0.0001
	Tofacitinib 10 mg BID	330	225 (68.18)	2.56	53.23	4.30	44.81, 61.65	<0.0001	1.91	3.64	-5.22, 9.05	0.5991
	Etanercept 50 mg BIW	335	222 (66.27)	2.58	51.32	4.31	42.87, 59.76	<0.0001				
	Placebo	107	16 (14.95)	3.45								

PASI75 response was defined as at least 75% reduction in PASI relative to Baseline/Day 1.
Baseline was defined as the last observation up to first dosing date.
NRI = Any missing values were imputed as a failure; Normal approximation.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, NRI = Non-Responder Response Inputation, PASI = Psoriasis Area and Severity Index, PGA = Physician Global Assessment, SE = standard error.

Secondary Endpoint Results:

PASI75 Response During the 12 Week Treatment Period

The proportion of subjects achieving a PASI75 response increased from Week 4 through Week 12 in all active treatment groups. At Weeks 4 and 8, a greater percentage of subjects achieving a PASI75 response was observed in the tofacitinib 10 mg BID group compared to the other treatment groups. By Week 12, the percentage of subjects achieving a PASI75 response was similar in the tofacitinib 10 mg BID and the etanercept 50 mg BIW groups and numerically higher compared to the tofacitinib 5 mg BID group.

A statistically significantly greater proportion of subjects achieved PASI75 response at Weeks 4, 8, and 12 in all active treatment groups versus placebo (all 95% LCI >0). A summary of the number of subjects achieving PASI75 response during the 12-week double-blind treatment period is presented in Table 5.

Table 5. Proportion of Subjects Achieving PASI75 Response During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	326	5 (1.53)	0.68	1.53	0.68	0.20, 2.87	0.63	0.86	-1.05, 2.31
Tofacitinib 10 mg BID	327	9 (2.75)	0.90	2.75	0.90	0.98, 4.53	1.85	1.04	-0.20, 3.89
Etanercept 50 mg BIW	331	3 (0.91)	0.52	0.91	0.52	-0.11, 1.93			
Placebo	106	0 (0.00)	0						
Week 4									
Tofacitinib 5 mg BID	319	33 (10.34)	1.71	10.34	1.71	7.00, 13.69	2.11	2.28	-2.36, 6.59
Tofacitinib 10 mg BID	323	64 (19.81)	2.22	19.81	2.22	15.47, 24.16	11.58	2.69	6.32, 16.85
Etanercept 50 mg BIW	328	27 (8.23)	1.52	8.23	1.52	5.26, 11.21			
Placebo	102	0 (0.00)	0						
Week 8									
Tofacitinib 5 mg BID	315	90 (28.57)	2.55	25.54	3.07	19.52, 31.57	-14.15	3.75	-21.50, -6.81
Tofacitinib 10 mg BID	319	167 (52.35)	2.80	49.32	3.28	42.88, 55.76	9.63	3.92	1.94, 17.32
Etanercept 50 mg BIW	323	138 (42.72)	2.75	39.69	3.25	33.33, 46.06			
Placebo	99	3 (3.03)	1.72						
Week 12									
Tofacitinib 5 mg BID	313	130 (41.53)	2.79	35.22	3.74	27.89, 42.55	-22.22	3.90	-29.87, -14.57
Tofacitinib 10 mg BID	311	210 (67.52)	2.66	61.21	3.64	54.07, 68.35	3.77	3.81	-3.70, 11.24
Etanercept 50 mg BIW	309	197 (63.75)	2.73	57.44	3.70	50.18, 64.69			
Placebo	95	6 (6.32)	2.50						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PASI = Psoriasis Area and Severity Index, SE = standard error.

The Percent Change From Baseline in PASI at Various Time Points Through Week 12

Table 6 provides descriptive statistics of the percent change From Baseline PASI score.

Table 6. Descriptive Statistics of Percent Change From Baseline PASI Score During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Week 2	Tofacitinib 5 mg BID	326	-21.15	1.2
	Tofacitinib 10 mg BID	327	-28.76	1.27
	Etanercept 50 mg BIW	331	-24.03	1.12
	Placebo	106	-7.08	1.97
Week 4	Tofacitinib 5 mg BID	319	-37.27	1.63
	Tofacitinib 10 mg BID	323	-49.58	1.51
	Etanercept 50 mg BIW	328	-44.63	1.31
	Placebo	102	-10.15	2.7
Week 8	Tofacitinib 5 mg BID	315	-52.46	2.06
	Tofacitinib 10 mg BID	319	-68.58	1.55
	Etanercept 50 mg BIW	323	-65.85	1.43
	Placebo	99	-20.2	3.14
Week 12	Tofacitinib 5 mg BID	313	-59.2	2.33
	Tofacitinib 10 mg BID	311	-75.99	1.49
	Etanercept 50 mg BIW	309	-75.62	1.49
	Placebo	95	-21.68	3.75

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, PASI = Psoriasis Area and Severity Index, SE = standard error.

Proportion of Subjects Achieving at Least a 50% Reduction in PASI Relative to Baseline (PASI50) at Various Time Points Through Week 12

A greater percentage of subjects in all active treatment groups, at each time point, achieved a PASI50 response compared to placebo; the greatest difference from placebo was observed with the tofacitinib 10 mg BID group and etanercept 50 mg BIW group at Week 12 (Table 7).

Table 7. Proportion of Subjects Achieving PASI50 Response During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	326	35 (10.74)	1.71	9.79	1.95	5.96, 13.62	-0.44	2.44	-5.22, 4.33
Tofacitinib 10 mg BID	327	60 (18.35)	2.14	17.41	2.34	12.82, 21.99	7.17	2.75	1.77, 12.57
Etanercept 50 mg BIW	331	37 (11.18)	1.73	10.23	1.97	6.37, 14.10			
Placebo	106	1 (0.94)	0.94						
Week 4									
Tofacitinib 5 mg BID	319	106 (33.23)	2.64	26.37	3.64	19.24, 33.49	-15.55	3.82	-23.03, -8.07
Tofacitinib 10 mg BID	323	163 (50.46)	2.78	43.60	3.74	36.27, 50.94	1.68	3.92	-6.00, 9.36
Etanercept 50 mg BIW	328	160 (48.78)	2.76	41.92	3.73	34.61, 49.22			
Placebo	102	7 (6.86)	2.50						
Week 8									
Tofacitinib 5 mg BID	315	186 (59.05)	2.77	38.85	4.89	29.25, 48.44	-18.04	3.63	-25.15, -10.94
Tofacitinib 10 mg BID	319	249 (78.06)	2.32	57.85	4.65	48.73, 66.97	0.97	3.29	-5.49, 7.42
Etanercept 50 mg BIW	323	249 (77.09)	2.34	56.89	4.66	47.75, 66.03			
Placebo	99	20 (20.20)	4.04						
Week 12									
Tofacitinib 5 mg BID	313	216 (69.01)	2.61	45.85	5.06	35.94, 55.76	-18.05	3.24	-24.39, -11.70
Tofacitinib 10 mg BID	311	266 (85.53)	1.99	62.37	4.77	53.03, 71.71	-1.52	2.76	-6.94, 3.89
Etanercept 50 mg BIW	309	269 (87.06)	1.91	63.90	4.73	54.63, 73.17			
Placebo	95	22 (23.16)	4.33						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PASI50 = Psoriasis Area and Severity Index 50, SE = standard error.

Proportion of Subjects Achieving at Least a 90% Reduction in PASI Relative to Baseline (PASI90) at Various Time Points Through Week 12

The percentage of subjects achieving a PASI90 was greater for all active treatment groups compared to placebo at Week 4 through Week 12, with the highest difference versus placebo observed at Week 12 for the tofacitinib 5 mg BID, tofacitinib 10 mg BID and etanercept 50 mg BIW groups, respectively (Table 8).

Table 8. Proportion of Subjects Achieving PASI90 Response During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	326	0 (0.00)	0.00	0.00	0.00	0.00, 0.00	-0.30	0.30	-0.89, 0.29
Tofacitinib 10 mg BID	327	2 (0.61)	0.43	0.61	0.43	-0.23, 1.46	0.31	0.53	-0.72, 1.34
Etanercept 50 mg BIW	331	1 (0.30)	0.30	0.30	0.30	-0.29, 0.89			
Placebo	106	0 (0.00)	0.00						
Week 4									
Tofacitinib 5 mg BID	319	5 (1.57)	0.70	1.57	0.70	0.20, 2.93	-0.26	1.02	-2.25, 1.73
Tofacitinib 10 mg BID	323	15 (4.64)	1.17	4.64	1.17	2.35, 6.94	2.81	1.39	0.10, 5.53
Etanercept 50 mg BIW	328	6 (1.83)	0.74	1.83	0.74	0.38, 3.28			
Placebo	102	0 (0.00)	0.00						
Week 8									
Tofacitinib 5 mg BID	315	38 (12.06)	1.84	12.06	1.84	8.47, 15.66	-3.73	2.74	-9.09, 1.64
Tofacitinib 10 mg BID	319	83 (26.02)	2.46	26.02	2.46	21.20, 30.83	10.23	3.19	3.98, 16.47
Etanercept 50 mg BIW	323	51 (15.79)	2.03	15.79	2.03	11.81, 19.77			
Placebo	99	0 (0.00)	0.00						
Week 12									
Tofacitinib 5 mg BID	313	69 (22.04)	2.34	20.99	2.57	15.96, 26.02	-12.91	3.58	-19.93, -5.88
Tofacitinib 10 mg BID	311	119 (38.26)	2.76	37.21	2.95	31.43, 42.99	3.31	3.87	-4.27, 10.89
Etanercept 50 mg BIW	309	108 (34.95)	2.71	33.90	2.91	28.20, 39.60			
Placebo	95	1 (1.05)	1.05						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PASI90 = Psoriasis Area and Severity Index 90, SE = standard error.

Time to PASI50 and PASI75 Responses

In the evaluation of time to achieve PASI50, the shortest estimated median time-to-event (response) was observed in the tofacitinib 10 mg BID group (5.0 weeks, 95% CI [4.1, 8.0]), followed by the etanercept 50 mg BIW group (7.9 weeks, 95% CI [4.4, 8.0]) and the tofacitinib 5 mg BID group (8.1 weeks, 95% CI could not be estimated using LogLog transformation).

In the evaluation of time to achieve at least a 75% reduction in PASI relative to Baseline, the shortest median time-to-response was observed in the tofacitinib 10 mg BID group (8.6 weeks, 95% CI [8.1, 12.1]), followed by the etanercept 50 mg BIW group (12.1 weeks, 95% CI [11.1, 12.1]), and tofacitinib 5 mg BID group (12.6 weeks, 95% CI [12.4, 13.1]).

Proportion of Subjects With a PASI Score ≥125% of the Baseline PASI Score at Various Time Points Through Week 12

The percentage of subjects with a PASI score ≥125% of the baseline value was small for all groups including placebo at Weeks 2, 4, 8, and 12 (Table 9).

During the 12-week treatment period, 15 [4.6%] subjects in the tofacitinib 5 mg BID group and 17 [15.9%] subjects in the placebo group had at least 1 PASI score of ≥125% of the baseline value compared to 6 (1.8%) subjects in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups, respectively.

Table 9. Proportion of Subjects With PASI Score ≥125% of Baseline During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	326	3 (0.92)	0.53	-3.80	2.13	-7.96, 0.37	0.62	0.61	-0.58, 1.81
Tofacitinib 10 mg BID	327	2 (0.61)	0.43	-4.11	2.10	-8.23, 0.02	0.31	0.53	-0.72, 1.34
Etanercept 50 mg BIW	331	1 (0.30)	0.30	-4.41	2.08	-8.49, -0.34			
Placebo	106	5 (4.72)	2.06						
Week 4									
Tofacitinib 5 mg BID	319	7 (2.19)	0.82	-6.63	2.93	-12.36, -0.89	1.28	0.97	-0.63, 3.19
Tofacitinib 10 mg BID	323	3 (0.93)	0.53	-7.89	2.86	-13.50, -2.29	0.01	0.75	-1.45, 1.48
Etanercept 50 mg BIW	328	3 (0.91)	0.53	-7.91	2.86	-13.51, -2.31			
Placebo	102	9 (8.82)	2.81						
Week 8									
Tofacitinib 5 mg BID	315	8 (2.54)	0.89	-4.53	2.72	-9.87, 0.81	2.23	0.94	0.39, 4.07
Tofacitinib 10 mg BID	319	1 (0.31)	0.31	-6.76	2.60	-11.84, -1.67	0.00	0.44	-0.86, 0.87
Etanercept 50 mg BIW	323	1 (0.31)	0.31	-6.76	2.59	-11.85, -1.68			
Placebo	99	7 (7.07)	2.58						
Week 12									
Tofacitinib 5 mg BID	313	9 (2.88)	0.94	-4.49	2.84	-10.06, 1.08	1.90	1.10	-0.25, 4.05
Tofacitinib 10 mg BID	311	1 (0.32)	0.32	-7.05	2.70	-12.34, -1.76	-0.65	0.64	-1.91, 0.61
Etanercept 50 mg BIW	309	3 (0.97)	0.56	-6.40	2.74	-11.76, -1.03			
Placebo	95	7 (7.37)	2.68						
Overall									
Tofacitinib 5 mg BID	327	15 (4.59)	1.16	-11.30	3.72	-18.59, -4.01	2.79	1.37	0.11, 5.47
Tofacitinib 10 mg BID	329	6 (1.82)	0.74	-14.06	3.61	-21.14, -6.99	0.03	1.04	-2.00, 2.06
Etanercept 50 mg BIW	334	6 (1.80)	0.73	-14.09	3.61	-21.16, -7.02			
Placebo	107	17 (15.89)	3.53						

Overall n indicates the total number of subjects with PASI Score ≥125% of Baseline at least once during Weeks 2-12.
95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PASI = Psoriasis Area and Severity Index, SE = standard error.

PASI Component Scores

Descriptive statistics of PASI component scores (erythema, induration, scaling) and change from Baseline in PASI component scores by body region during the 12-week double-blind treatment period are presented in Table 10.

Mean Baseline PASI scores for each individual component (erythema, induration and scaling), at each body region, were similar between all treatment groups.

All active treatment groups showed a greater change (decrease) from Baseline in PASI component scores compared to placebo for all body regions, and at each time point.

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
Head/neck	Erythema	Baseline						
		Tofacitinib 5 mg BID	329	2.28	0.05			
		Tofacitinib 10 mg BID	329	2.36	0.05			
		Etanercept 50 mg BIW	335	2.32	0.05			
		Placebo	107	2.40	0.09			
		Week 2						
		Tofacitinib 5 mg BID	326	1.82	0.05	326	-0.46	0.04
		Tofacitinib 10 mg BID	326	1.65	0.05	326	-0.72	0.05
		Etanercept 50 mg BIW	331	1.76	0.06	331	-0.56	0.04
		Placebo	106	2.27	0.09	106	-0.15	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	1.48	0.05	320	-0.80	0.06
		Tofacitinib 10 mg BID	323	1.18	0.05	323	-1.19	0.06
		Etanercept 50 mg BIW	328	1.23	0.05	328	-1.10	0.05
		Placebo	102	2.03	0.09	102	-0.32	0.07
		Week 8						
		Tofacitinib 5 mg BID	315	1.19	0.06	315	-1.09	0.06
		Tofacitinib 10 mg BID	319	0.78	0.05	319	-1.59	0.06
		Etanercept 50 mg BIW	323	0.69	0.05	323	-1.63	0.06
		Placebo	99	1.89	0.10	99	-0.54	0.10
		Week 12						
		Tofacitinib 5 mg BID	313	1.04	0.06	313	-1.25	0.07
		Tofacitinib 10 mg BID	311	0.65	0.05	311	-1.73	0.07
		Etanercept 50 mg BIW	309	0.48	0.04	309	-1.83	0.06
		Placebo	95	1.74	0.11	95	-0.64	0.12
Head/neck	Induration	Baseline						
		Tofacitinib 5 mg BID	329	2.04	0.05			
		Tofacitinib 10 mg BID	329	2.08	0.05			
		Etanercept 50 mg BIW	335	1.96	0.06			
		Placebo	107	2.12	0.10			
		Week 2						
		Tofacitinib 5 mg BID	326	1.60	0.05	326	-0.44	0.04
		Tofacitinib 10 mg BID	326	1.44	0.05	326	-0.65	0.05

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Etanercept 50 mg BIW	331	1.46	0.06	331	-0.49	0.04
		Placebo	106	1.97	0.10	106	-0.17	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	1.21	0.05	320	-0.83	0.06
		Tofacitinib 10 mg BID	323	0.94	0.05	323	-1.15	0.06
		Etanercept 50 mg BIW	328	1.01	0.05	328	-0.95	0.05
		Placebo	102	1.69	0.10	102	-0.39	0.08
		Week 8						
		Tofacitinib 5 mg BID	315	0.96	0.05	315	-1.08	0.06
		Tofacitinib 10 mg BID	319	0.59	0.05	319	-1.50	0.06
		Etanercept 50 mg BIW	323	0.54	0.05	323	-1.41	0.06
		Placebo	99	1.57	0.10	99	-0.58	0.10
		Week 12						
		Tofacitinib 5 mg BID	313	0.87	0.05	313	-1.19	0.06
		Tofacitinib 10 mg BID	311	0.49	0.04	311	-1.61	0.06
		Etanercept 50 mg BIW	309	0.37	0.04	309	-1.57	0.06
		Placebo	95	1.41	0.11	95	-0.71	0.11
Head/neck	Scaling	Baseline						
		Tofacitinib 5 mg BID	329	2.29	0.06			
		Tofacitinib 10 mg BID	329	2.38	0.06			
		Etanercept 50 mg BIW	335	2.28	0.06			
		Placebo	107	2.33	0.10			
		Week 2						
		Tofacitinib 5 mg BID	326	1.75	0.06	326	-0.53	0.04
		Tofacitinib 10 mg BID	326	1.63	0.06	326	-0.76	0.05
		Etanercept 50 mg BIW	331	1.60	0.06	331	-0.67	0.05
		Placebo	106	2.15	0.10	106	-0.20	0.07
		Week 4						
		Tofacitinib 5 mg BID	320	1.38	0.06	320	-0.91	0.06
		Tofacitinib 10 mg BID	323	1.07	0.06	323	-1.30	0.07
		Etanercept 50 mg BIW	328	1.16	0.05	328	-1.13	0.06
		Placebo	102	1.80	0.11	102	-0.48	0.08
		Week 8						

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Tofacitinib 5 mg BID	315	1.12	0.06	315	-1.16	0.07
		Tofacitinib 10 mg BID	319	0.70	0.05	319	-1.70	0.06
		Etanercept 50 mg BIW	323	0.65	0.05	323	-1.62	0.06
		Placebo	99	1.66	0.11	99	-0.69	0.10
		Week 12						
		Tofacitinib 5 mg BID	313	0.98	0.06	313	-1.31	0.07
		Tofacitinib 10 mg BID	311	0.60	0.05	311	-1.78	0.07
		Etanercept 50 mg BIW	309	0.46	0.05	309	-1.81	0.07
		Placebo	95	1.51	0.11	95	-0.80	0.11
Upper limbs	Erythema	Baseline						
		Tofacitinib 5 mg BID	329	2.87	0.04			
		Tofacitinib 10 mg BID	329	2.87	0.04			
		Etanercept 50 mg BIW	335	2.88	0.04			
		Placebo	107	2.92	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.35	0.04	326	-0.52	0.04
		Tofacitinib 10 mg BID	326	2.18	0.05	326	-0.68	0.04
		Etanercept 50 mg BIW	331	2.27	0.05	331	-0.61	0.04
		Placebo	106	2.75	0.07	106	-0.18	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	1.92	0.05	320	-0.94	0.05
		Tofacitinib 10 mg BID	323	1.73	0.05	323	-1.13	0.05
		Etanercept 50 mg BIW	328	1.77	0.05	328	-1.11	0.04
		Placebo	102	2.61	0.07	102	-0.26	0.07
		Week 8						
		Tofacitinib 5 mg BID	315	1.55	0.05	315	-1.31	0.06
		Tofacitinib 10 mg BID	319	1.27	0.05	319	-1.60	0.06
		Etanercept 50 mg BIW	323	1.25	0.05	323	-1.62	0.05
		Placebo	99	2.42	0.08	99	-0.49	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.45	0.06	313	-1.42	0.07
		Tofacitinib 10 mg BID	311	1.07	0.05	311	-1.79	0.06
		Etanercept 50 mg BIW	309	0.94	0.05	309	-1.95	0.06

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Placebo	95	2.32	0.08	95	-0.58	0.09
Upper limbs	Induration	Baseline						
		Tofacitinib 5 mg BID	329	2.69	0.04			
		Tofacitinib 10 mg BID	329	2.76	0.04			
		Etanercept 50 mg BIW	335	2.72	0.04			
		Placebo	107	2.79	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.17	0.05	326	-0.52	0.04
		Tofacitinib 10 mg BID	326	2.03	0.05	326	-0.73	0.04
		Etanercept 50 mg BIW	331	2.13	0.05	331	-0.59	0.04
		Placebo	106	2.54	0.07	106	-0.25	0.05
		Week 4						
		Tofacitinib 5 mg BID	320	1.76	0.05	320	-0.94	0.06
		Tofacitinib 10 mg BID	323	1.54	0.05	323	-1.23	0.05
		Etanercept 50 mg BIW	328	1.59	0.05	328	-1.13	0.05
		Placebo	102	2.36	0.08	102	-0.39	0.07
		Week 8						
		Tofacitinib 5 mg BID	315	1.43	0.06	315	-1.26	0.06
		Tofacitinib 10 mg BID	319	1.13	0.05	319	-1.65	0.06
		Etanercept 50 mg BIW	323	1.18	0.05	323	-1.54	0.05
		Placebo	99	2.12	0.09	99	-0.67	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.31	0.06	313	-1.39	0.07
		Tofacitinib 10 mg BID	311	1.01	0.05	311	-1.77	0.06
		Etanercept 50 mg BIW	309	0.81	0.05	309	-1.92	0.06
		Placebo	95	2.08	0.09	95	-0.68	0.10
Upper limbs	Scaling	Baseline						
		Tofacitinib 5 mg BID	329	2.66	0.04			
		Tofacitinib 10 mg BID	329	2.72	0.04			
		Etanercept 50 mg BIW	335	2.73	0.04			
		Placebo	107	2.63	0.08			
		Week 2						
		Tofacitinib 5 mg BID	326	2.11	0.05	326	-0.56	0.04

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Tofacitinib 10 mg BID	326	2.00	0.05	326	-0.72	0.05
		Etanercept 50 mg BIW	331	2.03	0.05	331	-0.69	0.04
		Placebo	106	2.35	0.09	106	-0.28	0.07
		Week 4						
		Tofacitinib 5 mg BID	320	1.71	0.05	320	-0.96	0.05
		Tofacitinib 10 mg BID	323	1.50	0.05	323	-1.23	0.06
		Etanercept 50 mg BIW	328	1.54	0.05	328	-1.19	0.05
		Placebo	102	2.22	0.10	102	-0.38	0.08
		Week 8						
		Tofacitinib 5 mg BID	315	1.39	0.06	315	-1.28	0.06
		Tofacitinib 10 mg BID	319	1.11	0.05	319	-1.62	0.06
		Etanercept 50 mg BIW	323	1.07	0.05	323	-1.66	0.06
		Placebo	99	1.98	0.09	99	-0.64	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.30	0.06	313	-1.36	0.07
		Tofacitinib 10 mg BID	311	1.00	0.05	311	-1.73	0.06
		Etanercept 50 mg BIW	309	0.82	0.05	309	-1.92	0.06
		Placebo	95	1.95	0.10	95	-0.65	0.10
Trunk	Erythema	Baseline						
		Tofacitinib 5 mg BID	329	2.95	0.04			
		Tofacitinib 10 mg BID	329	2.88	0.04			
		Etanercept 50 mg BIW	335	2.91	0.04			
		Placebo	107	2.97	0.06			
		Week 2						
		Tofacitinib 5 mg BID	326	2.40	0.05	326	-0.54	0.04
		Tofacitinib 10 mg BID	326	2.20	0.05	326	-0.67	0.04
		Etanercept 50 mg BIW	331	2.27	0.05	331	-0.63	0.04
		Placebo	106	2.75	0.07	106	-0.23	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	2.03	0.05	320	-0.91	0.05
		Tofacitinib 10 mg BID	323	1.75	0.05	323	-1.13	0.05
		Etanercept 50 mg BIW	328	1.76	0.05	328	-1.16	0.05
		Placebo	102	2.59	0.07	102	-0.35	0.06

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Week 8						
		Tofacitinib 5 mg BID	315	1.71	0.06	315	-1.23	0.06
		Tofacitinib 10 mg BID	319	1.23	0.05	319	-1.66	0.06
		Etanercept 50 mg BIW	323	1.24	0.05	323	-1.67	0.06
		Placebo	99	2.41	0.09	99	-0.59	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.53	0.06	313	-1.41	0.07
		Tofacitinib 10 mg BID	311	0.97	0.06	311	-1.90	0.07
		Etanercept 50 mg BIW	309	0.89	0.05	309	-2.03	0.06
		Placebo	95	2.33	0.10	95	-0.67	0.10
Trunk	Induration	Baseline						
		Tofacitinib 5 mg BID	329	2.75	0.04			
		Tofacitinib 10 mg BID	329	2.70	0.05			
		Etanercept 50 mg BIW	335	2.66	0.05			
		Placebo	107	2.66	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.26	0.05	326	-0.49	0.04
		Tofacitinib 10 mg BID	326	2.01	0.05	326	-0.69	0.04
		Etanercept 50 mg BIW	331	2.05	0.05	331	-0.61	0.04
		Placebo	106	2.40	0.07	106	-0.27	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	1.83	0.05	320	-0.93	0.06
		Tofacitinib 10 mg BID	323	1.50	0.05	323	-1.20	0.06
		Etanercept 50 mg BIW	328	1.50	0.05	328	-1.17	0.05
		Placebo	102	2.26	0.07	102	-0.37	0.07
		Week 8						
		Tofacitinib 5 mg BID	315	1.50	0.06	315	-1.26	0.06
		Tofacitinib 10 mg BID	319	0.97	0.05	319	-1.74	0.06
		Etanercept 50 mg BIW	323	0.98	0.05	323	-1.68	0.06
		Placebo	99	2.06	0.09	99	-0.62	0.10
		Week 12						
		Tofacitinib 5 mg BID	313	1.33	0.06	313	-1.43	0.07
		Tofacitinib 10 mg BID	311	0.80	0.05	311	-1.91	0.07

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Etanercept 50 mg BIW	309	0.66	0.05	309	-1.99	0.06
		Placebo	95	2.03	0.09	95	-0.64	0.11
Trunk	Scaling	Baseline						
		Tofacitinib 5 mg BID	329	2.64	0.04			
		Tofacitinib 10 mg BID	329	2.66	0.05			
		Etanercept 50 mg BIW	335	2.57	0.05			
		Placebo	107	2.61	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.12	0.05	326	-0.52	0.05
		Tofacitinib 10 mg BID	326	1.92	0.06	326	-0.74	0.05
		Etanercept 50 mg BIW	331	1.93	0.05	331	-0.64	0.05
		Placebo	106	2.36	0.09	106	-0.25	0.07
		Week 4						
		Tofacitinib 5 mg BID	320	1.73	0.05	320	-0.92	0.06
		Tofacitinib 10 mg BID	323	1.39	0.05	323	-1.27	0.06
		Etanercept 50 mg BIW	328	1.44	0.05	328	-1.15	0.05
		Placebo	102	2.12	0.09	102	-0.47	0.08
		Week 8						
		Tofacitinib 5 mg BID	315	1.47	0.06	315	-1.19	0.06
		Tofacitinib 10 mg BID	319	0.94	0.05	319	-1.71	0.06
		Etanercept 50 mg BIW	323	0.90	0.05	323	-1.67	0.06
		Placebo	99	1.86	0.08	99	-0.75	0.09
		Week 12						
		Tofacitinib 5 mg BID	313	1.28	0.06	313	-1.38	0.07
		Tofacitinib 10 mg BID	311	0.74	0.05	311	-1.92	0.06
		Etanercept 50 mg BIW	309	0.62	0.05	309	-1.94	0.06
		Placebo	95	1.91	0.10	95	-0.71	0.10
Lower limbs	Erythema	Baseline						
		Tofacitinib 5 mg BID	329	3.12	0.03			
		Tofacitinib 10 mg BID	329	3.13	0.04			
		Etanercept 50 mg BIW	335	3.14	0.03			
		Placebo	107	3.10	0.06			
		Week 2						

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Tofacitinib 5 mg BID	326	2.60	0.04	326	-0.52	0.04
		Tofacitinib 10 mg BID	326	2.44	0.05	326	-0.69	0.04
		Etanercept 50 mg BIW	331	2.61	0.05	331	-0.53	0.04
		Placebo	106	2.92	0.07	106	-0.20	0.05
		Week 4						
		Tofacitinib 5 mg BID	320	2.17	0.05	320	-0.95	0.05
		Tofacitinib 10 mg BID	323	1.98	0.05	323	-1.15	0.05
		Etanercept 50 mg BIW	328	2.15	0.05	328	-1.00	0.04
		Placebo	102	2.75	0.07	102	-0.32	0.06
		Week 8						
		Tofacitinib 5 mg BID	315	1.77	0.06	315	-1.34	0.06
		Tofacitinib 10 mg BID	319	1.50	0.05	319	-1.63	0.05
		Etanercept 50 mg BIW	323	1.62	0.05	323	-1.51	0.05
		Placebo	99	2.55	0.08	99	-0.55	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.56	0.06	313	-1.55	0.07
		Tofacitinib 10 mg BID	311	1.21	0.06	311	-1.92	0.07
		Etanercept 50 mg BIW	309	1.35	0.05	309	-1.80	0.06
		Placebo	95	2.45	0.09	95	-0.61	0.09
Lower limbs	Induration	Baseline						
		Tofacitinib 5 mg BID	329	2.94	0.04			
		Tofacitinib 10 mg BID	329	2.97	0.04			
		Etanercept 50 mg BIW	335	3.00	0.04			
		Placebo	107	2.92	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.47	0.04	326	-0.47	0.04
		Tofacitinib 10 mg BID	326	2.26	0.05	326	-0.71	0.04
		Etanercept 50 mg BIW	331	2.45	0.04	331	-0.56	0.04
		Placebo	106	2.69	0.07	106	-0.24	0.05
		Week 4						
		Tofacitinib 5 mg BID	320	2.03	0.05	320	-0.92	0.05
		Tofacitinib 10 mg BID	323	1.72	0.05	323	-1.25	0.05
		Etanercept 50 mg BIW	328	1.92	0.05	328	-1.08	0.05

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Placebo	102	2.54	0.07	102	-0.35	0.07
		Week 8						
		Tofacitinib 5 mg BID	315	1.58	0.06	315	-1.37	0.06
		Tofacitinib 10 mg BID	319	1.18	0.05	319	-1.80	0.06
		Etanercept 50 mg BIW	323	1.38	0.05	323	-1.62	0.06
		Placebo	99	2.25	0.08	99	-0.66	0.08
		Week 12						
		Tofacitinib 5 mg BID	313	1.40	0.06	313	-1.56	0.07
		Tofacitinib 10 mg BID	311	0.97	0.05	311	-2.01	0.06
		Etanercept 50 mg BIW	309	1.10	0.06	309	-1.91	0.06
		Placebo	95	2.21	0.08	95	-0.67	0.09
Lower limbs	Scaling	Baseline						
		Tofacitinib 5 mg BID	329	2.91	0.04			
		Tofacitinib 10 mg BID	329	2.95	0.04			
		Etanercept 50 mg BIW	335	2.98	0.04			
		Placebo	107	2.89	0.07			
		Week 2						
		Tofacitinib 5 mg BID	326	2.36	0.05	326	-0.55	0.04
		Tofacitinib 10 mg BID	326	2.25	0.05	326	-0.69	0.05
		Etanercept 50 mg BIW	331	2.31	0.05	331	-0.67	0.04
		Placebo	106	2.62	0.09	106	-0.27	0.06
		Week 4						
		Tofacitinib 5 mg BID	320	1.98	0.05	320	-0.94	0.05
		Tofacitinib 10 mg BID	323	1.69	0.06	323	-1.26	0.06
		Etanercept 50 mg BIW	328	1.81	0.05	328	-1.18	0.05
		Placebo	102	2.44	0.09	102	-0.43	0.09
		Week 8						
		Tofacitinib 5 mg BID	315	1.60	0.06	315	-1.31	0.06
		Tofacitinib 10 mg BID	319	1.21	0.06	319	-1.74	0.06
		Etanercept 50 mg BIW	323	1.32	0.05	323	-1.67	0.06
		Placebo	99	2.11	0.1	99	-0.75	0.09
		Week 12						
		Tofacitinib 5 mg BID	313	1.39	0.06	313	-1.53	0.07

Table 10. Descriptive Statistics and Change From Baseline of PASI Component Scores (Erythema, Induration, Scaling) by Body Region During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Body Region	PASI Component Score	Visit/Treatment	Actual Values			Change From Baseline		
			N	Mean	SE	N	Mean	SE
		Tofacitinib 10 mg BID	311	0.96	0.06	311	-1.99	0.06
		Etanercept 50 mg BIW	309	1.08	0.06	309	-1.92	0.07
		Placebo	95	2.09	0.10	95	-0.76	0.10

Normal approximation; PASI75 response was defined as at least 75% reduction in PASI relative to Baseline/Day 1.
Baseline was defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria,
PASI = Psoriasis Area and Severity Index, SE = standard error.

PGA Response of "Clear" or "Almost Clear" During the 12-Week Treatment Period

At Baseline approximately 82% of subjects had a PGA score of 3 (moderate) and 17% had a PGA score of 4 (severe).

The percentage of subjects achieving a PGA of "clear" or "almost clear" was statistically significantly greater for all active treatment groups compared to placebo at each time point ($p<0.01$), with the greatest difference from placebo observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups at Week 12; a similar proportion of subjects in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups achieved a PGA of "clear" or "almost clear" at Week 12, with a greater response than that observed for the tofacitinib 5 mg BID group.

The proportion of subjects achieving a PGA of "clear" or "almost clear" during the 12-week double-blind treatment period is presented in Table 11.

Table 11. Proportion of Subjects Achieving Physician Global Assessment (PGA) Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	325	22 (6.77)	1.39	4.90	1.91	1.15, 8.65	-1.09	2.03	-5.07, 2.90
Tofacitinib 10 mg BID	326	35 (10.74)	1.71	8.87	2.16	4.64, 13.10	2.88	2.26	-1.56, 7.32
Etanercept 50 mg BIW	331	26 (7.85)	1.48	5.99	1.98	2.11, 9.86			
Placebo	107	2 (1.87)	1.31						
Week 4									
Tofacitinib 5 mg BID	320	68 (21.25)	2.29	17.33	2.99	11.47, 23.18	-7.10	3.38	-13.73, -0.48
Tofacitinib 10 mg BID	323	116 (35.91)	2.67	31.99	3.29	25.54, 38.44	7.56	3.65	0.41, 14.71
Etanercept 50 mg BIW	328	93 (28.35)	2.49	24.43	3.14	18.27, 30.60			
Placebo	102	4 (3.92)	1.92						
Week 8									
Tofacitinib 5 mg BID	314	127 (40.45)	2.77	27.45	4.36	18.91, 35.99	-20.42	3.88	-28.03, -12.82
Tofacitinib 10 mg BID	316	201 (63.61)	2.71	50.61	4.32	42.15, 59.07	2.74	3.84	-4.78, 10.26
Etanercept 50 mg BIW	322	196 (60.87)	2.72	47.87	4.33	39.39, 56.35			
Placebo	100	13 (13.00)	3.36						
Week 12									
Tofacitinib 5 mg BID	313	155 (49.52)	2.83	32.68	4.77	23.33, 42.02	-22.32	3.81	-29.80, -14.85
Tofacitinib 10 mg BID	311	225 (72.35)	2.54	55.51	4.60	46.49, 64.52	0.50	3.60	-6.56, 7.56
Etanercept 50 mg BIW	309	222 (71.84)	2.56	55.00	4.61	45.96, 64.05			
Placebo	95	16 (16.84)	3.84						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, PGA = Physician Global Assessment, SE = standard error.

Proportion of Subjects in Each PGA Category at Various Time Points Through Week 12

The proportion of subjects in each PGA category at various time points through Week 12 is shown in Table 12.

Table 12. Descriptive Statistics of Physician Global Assessment (PGA) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	PGA Category	Tofacitinib 5 mg BID n (%)	Tofacitinib 10 mg BID n (%)	Etanercept 50 mg BIW n (%)	Placebo n (%)
Baseline	Clear (0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Almost clear (1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Mild (2)	6 (1.8)	4 (1.2)	4 (1.2)	3 (2.8)
	Moderate (3)	264 (80.2)	275 (83.3)	271 (80.9)	88 (82.2)
	Severe (4)	59 (17.9)	51 (15.5)	60 (17.9)	16 (15.0)
	N (total)	329	330	335	107
Week 2	Clear (0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Almost clear (1)	22 (6.8)	35 (10.7)	26 (7.9)	2 (1.9)
	Mild (2)	125 (38.5)	156 (47.9)	141 (42.6)	27 (25.2)
	Moderate (3)	159 (48.9)	125 (38.3)	151 (45.6)	69 (64.5)
	Severe (4)	19 (5.8)	10 (3.1)	13 (3.9)	9 (8.4)
	N (total)	325	326	331	107
Week 4	Clear (0)	6 (1.9)	8 (2.5)	2 (0.6)	0 (0.0)
	Almost clear (1)	62 (19.4)	108 (33.4)	91 (27.7)	4 (3.9)
	Mild (2)	148 (46.3)	143 (44.3)	169 (51.5)	35 (34.3)
	Moderate (3)	96 (30.0)	57 (17.6)	64 (19.5)	57 (55.9)
	Severe (4)	8 (2.5)	7 (2.2)	2 (0.6)	6 (5.9)
	N (total)	320	323	328	102
Week 8	Clear (0)	17 (5.4)	45 (14.2)	29 (9.0)	0 (0.0)
	Almost clear (1)	110 (35.0)	156 (49.4)	167 (51.9)	13 (13.0)
	Mild (2)	130 (41.4)	79 (25.0)	97 (30.1)	35 (35.0)
	Moderate (3)	50 (15.9)	34 (10.8)	26 (8.1)	49 (49.0)
	Severe (4)	7 (2.2)	2 (0.6)	3 (0.9)	3 (3.0)
	N (total)	314	316	322	100
Week 12	Clear (0)	37 (11.8)	84 (27.0)	65 (21.0)	2 (2.1)
	Almost clear (1)	118 (37.7)	141 (45.3)	157 (50.8)	14 (14.7)
	Mild (2)	105 (33.5)	60 (19.3)	66 (21.4)	35 (36.8)
	Moderate (3)	49 (15.7)	23 (7.4)	17 (5.5)	40 (42.1)
	Severe (4)	4 (1.3)	3 (1.0)	4 (1.3)	4 (4.2)
	N (total)	313	311	309	95

Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, n = number of subjects meeting prespecified criteria, N = total number of subjects, PGA = Physician Global Assessment.

Total Psoriatic BSA

Mean Baseline values for the percentage of total psoriatic BSA were similar between treatment groups. Overall, a decrease in total psoriatic BSA was observed for all active treatment groups at all time points after Baseline at Week 12 (Table 13).

Table 13. Descriptive Statistics of Total Psoriatic BSA (%) During the 12-Week Double-Blind Treatment

	Tofacitinib		Etanercept	Placebo
	5 mg BID	10 mg BID	50 mg BIW	
Baseline				
N	329	329	335	107
Mean (SE)	32.15 (0.98)	31.74 (0.95)	30.63 (1.00)	31.88 (1.62)
Week 2				
N	326	326	331	106
Mean (SE)	29.53 (0.96)	28.12 (0.94)	28.29 (0.97)	32.03 (1.76)
Week 4				
N	320	323	328	102
Mean (SE)	25.98 (0.96)	22.88 (0.93)	24.82 (0.95)	32.47 (1.89)
Week 8				
N	315	319	323	99
Mean (SE)	19.74 (0.98)	14.76 (0.89)	15.42 (0.81)	31.00 (1.98)
Week 12				
N	313	311	309	95
Mean (SE)	16.04 (0.94)	10.55 (0.77)	10.60 (0.76)	29.77 (2.12)

BID = twice daily, BIW = twice weekly, BSA = Body Surface Area, N = number of subjects, SE = standard error.

Descriptive statistics of the percent change from Baseline in total psoriatic BSA during the 12-week double-blind treatment period are summarized in Table 14.

Table 14. Descriptive Statistics of Percent Change From Baseline Total Psoriatic Body Surface Area (BSA) (%) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

	N	Mean	SE
Week 2			
Tofacitinib 5 mg BID	326	-7.54	1.23
Tofacitinib 10 mg BID	326	-11.71	1.12
Etanercept 50 mg BIW	331	-7.54	0.96
Placebo	106	0.23	1.89
Week 4			
Tofacitinib 5 mg BID	320	-19.90	1.66
Tofacitinib 10 mg BID	323	-29.17	1.69
Etanercept 50 mg BIW	328	-19.60	1.46
Placebo	102	1.58	2.84
Week 8			
Tofacitinib 5 mg BID	315	-37.81	2.81
Tofacitinib 10 mg BID	319	-55.02	1.93
Etanercept 50 mg BIW	323	-48.65	1.91
Placebo	99	-1.33	3.57
Week 12			
Tofacitinib 5 mg BID	313	-47.66	3.35
Tofacitinib 10 mg BID	311	-67.51	1.86
Etanercept 50 mg BIW	309	-64.91	1.91
Placebo	95	-6.68	4.06

BID = twice daily, BIW = twice weekly, BSA = body surface area, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Actual and Change From Baseline in the Itch Severity Item (ISI) Score at Various Time Points Through Week 12

Mean ISI scores were similar between all treatment groups at Baseline (tofacitinib 5 mg BID: 5.19 [0.16 standard error (SE)]; tofacitinib 10 mg BID: 5.26 [0.16 SE]; etanercept 50 mg BIW: 5.23 [0.15 SE]; and placebo: 5.15 [0.27 SE]), indicating a moderate level of itching (Table 15).

Mean ISI scores decreased at each time point for all active treatment groups, with the largest mean decreases observed in the tofacitinib 10 mg BID group at each time point (LS mean change from Baseline [SE] to Week 12: -3.96 [0.18]) compared to the etanercept 50 mg BIW group (-3.46 [0.19]), tofacitinib 5 mg BID group (-3.18 [0.18]) and placebo group (-0.43 [0.28]) (Table 16).

Table 15. Descriptive Statistics of Itch Severity Item (ISI) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Baseline	Tofacitinib 5 mg BID	305	5.19	0.16
	Tofacitinib 10 mg BID	308	5.26	0.16
	Etanercept 50 mg BIW	305	5.23	0.15
	Placebo	107	5.15	0.27
Week 2	Tofacitinib 5 mg BID	325	3.47	0.15
	Tofacitinib 10 mg BID	322	2.87	0.14
	Etanercept 50 mg BIW	330	3.90	0.15
	Placebo	105	4.90	0.30
Week 4	Tofacitinib 5 mg BID	318	2.92	0.15
	Tofacitinib 10 mg BID	323	1.86	0.13
	Etanercept 50 mg BIW	328	2.97	0.13
	Placebo	101	4.65	0.31
Week 8	Tofacitinib 5 mg BID	313	2.11	0.14
	Tofacitinib 10 mg BID	315	1.22	0.11
	Etanercept 50 mg BIW	320	2.06	0.13
	Placebo	100	4.74	0.32
Week 12	Tofacitinib 5 mg BID	312	1.98	0.14
	Tofacitinib 10 mg BID	309	1.25	0.12
	Etanercept 50 mg BIW	311	1.72	0.13
	Placebo	95	4.75	0.32

Baseline ISI is the average score from diary 7 days prior to first dosing.
BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, ISI = Itch Severity Item, N = number of subjects, SE = standard error.

Table 16. Descriptive Statistics of Change From Baseline Itch Severity Item (ISI) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Week 2	Tofacitinib 5 mg BID	303	-1.73	0.15
	Tofacitinib 10 mg BID	300	-2.39	0.14
	Etanercept 50 mg BIW	301	-1.22	0.15
	Placebo	105	-0.26	0.22
Week 4	Tofacitinib 5 mg BID	295	-2.24	0.18
	Tofacitinib 10 mg BID	301	-3.43	0.17
	Etanercept 50 mg BIW	298	-2.20	0.15
	Placebo	101	-0.44	0.24
Week 8	Tofacitinib 5 mg BID	290	-3.01	0.18
	Tofacitinib 10 mg BID	295	-4.02	0.17
	Etanercept 50 mg BIW	293	-3.13	0.17
	Placebo	100	-0.46	0.26
Week 12	Tofacitinib 5 mg BID	289	-3.18	0.18
	Tofacitinib 10 mg BID	289	-3.96	0.18
	Etanercept 50 mg BIW	283	-3.46	0.19
	Placebo	95	-0.43	0.28

Baseline ISI is the average score from diary 7 days prior to first dosing.
BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, ISI = Itch Severity Item, N = number of subjects, SE = standard error.

Proportion of Subjects Achieving an ISI Score of '0' at Various Time Points Through Week 12

The proportion of subjects achieving ISI=0 (representing no itching) among subjects with ISI>0 at Baseline, during the 12-week double-blind treatment period are summarized in Table 17. The percentage of subjects achieving ISI=0 was numerically higher in the tofacitinib 10 mg BID group at each time point with the greatest difference observed at Week 12 (150 [48.4%] subjects) compared to the etanercept 50 mg BIW group (125 [38.1%] subjects), tofacitinib 5 mg BID group (94 [29.9%] subjects) and placebo group (6 [6.0%] subjects). A statistically greater proportion of subjects in all active treatment groups achieved ISI=0, compared to placebo at each time point ($p \leq 0.0001$).

Table 17. Proportion of Subjects Achieving Itch Severity Item (ISI)=0 During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	288	30 (10.42)	1.80	9.40	2.07	5.35, 13.45	-0.13	2.54	-5.10, 4.85
Tofacitinib 10 mg BID	281	39 (13.88)	2.06	12.86	2.30	8.35, 17.36	3.33	2.73	-2.02, 8.69
Etanercept 50 mg BIW	294	31 (10.54)	1.79	9.52	2.06	5.49, 13.56			
Placebo	98	1 (1.02)	1.02						
Week 4									
Tofacitinib 5 mg BID	281	44 (15.66)	2.17	13.53	2.63	8.38, 18.68	1.57	2.98	-4.26, 7.40
Tofacitinib 10 mg BID	283	97 (34.28)	2.82	32.15	3.19	25.90, 38.40	20.19	3.48	13.36, 27.01
Etanercept 50 mg BIW	291	41 (14.09)	2.04	11.96	2.52	7.01, 16.91			
Placebo	94	2 (2.13)	1.49						
Week 8									
Tofacitinib 5 mg BID	275	81 (29.45)	2.75	23.07	3.73	15.76, 30.38	0.78	3.83	-6.73, 8.30
Tofacitinib 10 mg BID	276	132 (47.83)	3.01	41.44	3.92	33.75, 49.13	19.15	4.02	11.27, 27.04
Etanercept 50 mg BIW	286	82 (28.67)	2.67	22.29	3.68	15.08, 29.49			
Placebo	94	6 (6.38)	2.52						
Week 12									
Tofacitinib 5 mg BID	275	87 (31.64)	2.80	24.89	3.86	17.32, 32.47	-8.44	4.07	-16.41, -0.47
Tofacitinib 10 mg BID	270	140 (51.85)	3.04	45.11	4.04	37.19, 53.03	11.78	4.23	3.48, 20.08
Etanercept 50 mg BIW	277	111 (40.07)	2.94	33.33	3.97	25.56, 41.11			
Placebo	89	6 (6.74)	2.66						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
Baseline ISI is the average score from diary 7 days prior to first dosing.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, ISI = Itch Severity Item, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

Actual and Change From Baseline on the Dermatology Life Quality Index (DLQI) Score at Various Time Points Through Week 12

Descriptive statistics for DLQI during the 12-week double-blind treatment are presented in Table 18. The mean DLQI scores were similar for all groups at Baseline and indicate that subjects' skin problems have a large effect on their quality of life. An improvement (reduction) in DLQI scores was observed for all treatment groups by Week 12 (mean [SE]: -7.33 [0.43] for the tofacitinib 5 mg BID group; -9.72 [0.40] for the tofacitinib 10 mg BID group; -8.97 [0.40] for the etanercept 50 mg BIW group; and -1.85 [0.66] for the placebo group (Table 19).

Table 18. Descriptive Statistics of Dermatology Life Quality Index (DLQI) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Baseline	Tofacitinib 5 mg BID	328	12.98	0.39
	Tofacitinib 10 mg BID	326	13.32	0.38
	Etanercept 50 mg BIW	332	12.73	0.38
	Placebo	106	12.27	0.69
Week 4	Tofacitinib 5 mg BID	318	7.82	0.36
	Tofacitinib 10 mg BID	323	5.95	0.32
	Etanercept 50 mg BIW	325	6.90	0.35
	Placebo	100	10.51	0.77
Week 12	Tofacitinib 5 mg BID	306	5.61	0.36
	Tofacitinib 10 mg BID	305	3.47	0.27
	Etanercept 50 mg BIW	307	3.84	0.30
	Placebo	93	10.33	0.81

BID = twice daily, BIW = twice weekly, DLQI = Dermatology Life Quality Index, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Table 19. Descriptive Statistics of Change From Baseline Dermatology Life Quality Index (DLQI) at Weeks 4 and 12 (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Week 4	Tofacitinib 5 mg BID	317	-5.28	0.35
	Tofacitinib 10 mg BID	319	-7.43	0.36
	Etanercept 50 mg BIW	322	-5.80	0.33
	Placebo	99	-1.64	0.55
Week 12	Tofacitinib 5 mg BID	305	-7.33	0.43
	Tofacitinib 10 mg BID	301	-9.72	0.40
	Etanercept 50 mg BIW	305	-8.97	0.40
	Placebo	93	-1.85	0.66

BID = twice daily, BIW = twice weekly, DLQI = Dermatology Life Quality Index, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

The Actual and Change From Baseline on the Subscale Scores of DLQI at Various Time Points Through Week 12

Descriptive statistics for DLQI and change from Baseline in DLQI during the 12-week double-blind treatment for the 6 subscale scores are presented in Table 20. In general, the

6 subscales followed the same trends as the DLQI total score (ie. a decrease [improvement] in scores with treatment from Baseline to Week 12 for all active treatment groups) with similar results observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups.

Table 20. Descriptive Statistics of Dermatology Life Quality Index (DLQI) and Change From Baseline: 6 Sub-Scales During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
Symptoms and Feelings Subscale Score							
Baseline	Tofacitinib 5 mg BID	328	3.44	0.09			
	Tofacitinib 10 mg BID	327	3.49	0.08			
	Etanercept 50 mg BIW	332	3.47	0.08			
	Placebo	106	3.46	0.16			
Week 4	Tofacitinib 5 mg BID	318	2.11	0.08	317	-1.34	0.09
	Tofacitinib 10 mg BID	323	1.63	0.07	320	-1.87	0.08
	Etanercept 50 mg BIW	324	1.94	0.07	321	-1.53	0.08
	Placebo	100	2.92	0.15	99	-0.53	0.15
Week 12	Tofacitinib 5 mg BID	306	1.60	0.09	305	-1.81	0.10
	Tofacitinib 10 mg BID	304	1.04	0.07	301	-2.41	0.10
	Etanercept 50 mg BIW	307	1.16	0.07	305	-2.30	0.10
	Placebo	93	2.85	0.17	93	-0.62	0.18
Daily Activities Subscale Score							
Baseline	Tofacitinib 5 mg BID	327	2.76	0.10			
	Tofacitinib 10 mg BID	327	2.85	0.09			
	Etanercept 50 mg BIW	332	2.76	0.09			
	Placebo	106	2.52	0.16			
Week 4	Tofacitinib 5 mg BID	318	1.68	0.08	316	-1.13	0.09
	Tofacitinib 10 mg BID	322	1.30	0.08	319	-1.57	0.09
	Etanercept 50 mg BIW	324	1.53	0.08	321	-1.21	0.09
	Placebo	100	2.28	0.18	99	-0.28	0.15
Week 12	Tofacitinib 5 mg BID	306	1.19	0.08	304	-1.58	0.10
	Tofacitinib 10 mg BID	305	0.70	0.07	302	-2.14	0.10
	Etanercept 50 mg BIW	306	0.79	0.07	304	-1.96	0.10
	Placebo	93	2.17	0.19	93	-0.34	0.19
Leisure Subscale Score							
Baseline	Tofacitinib 5 mg BID	326	2.52	0.11			
	Tofacitinib 10 mg BID	326	2.67	0.11			
	Etanercept 50 mg BIW	330	2.57	0.11			
	Placebo	106	2.25	0.17			
Week 4	Tofacitinib 5 mg BID	318	1.50	0.09	316	-1.03	0.10
	Tofacitinib 10 mg BID	322	1.14	0.08	318	-1.54	0.10

Table 20. Descriptive Statistics of Dermatology Life Quality Index (DLQI) and Change From Baseline: 6 Sub-Scales During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
	Etanercept 50 mg BIW	325	1.33	0.09	320	-1.24	0.10
	Placebo	100	1.84	0.18	99	-0.39	0.15
Week 12	Tofacitinib 5 mg BID	306	1.09	0.09	303	-1.41	0.11
	Tofacitinib 10 mg BID	305	0.70	0.07	301	-1.95	0.11
	Etanercept 50 mg BIW	307	0.71	0.07	303	-1.90	0.11
	Placebo	93	1.90	0.19	93	-0.31	0.18
Work and School Subscale Score							
Baseline	Tofacitinib 5 mg BID	328	1.12	0.06			
	Tofacitinib 10 mg BID	327	1.08	0.06			
	Etanercept 50 mg BIW	331	1.06	0.06			
	Placebo	106	0.97	0.11			
Week 4	Tofacitinib 5 mg BID	318	0.56	0.05	317	-0.56	0.06
	Tofacitinib 10 mg BID	323	0.46	0.05	320	-0.63	0.06
	Etanercept 50 mg BIW	325	0.54	0.05	321	-0.52	0.06
	Placebo	100	0.81	0.11	99	-0.13	0.10
Week 12	Tofacitinib 5 mg BID	306	0.41	0.04	305	-0.69	0.07
	Tofacitinib 10 mg BID	304	0.24	0.04	301	-0.86	0.06
	Etanercept 50 mg BIW	307	0.32	0.04	304	-0.77	0.07
	Placebo	92	0.83	0.12	92	-0.12	0.10
Personal Relationships Subscale Score							
Baseline	Tofacitinib 5 mg BID	328	1.95	0.11			
	Tofacitinib 10 mg BID	326	1.98	0.10			
	Etanercept 50 mg BIW	332	1.67	0.10			
	Placebo	106	1.89	0.18			
Week 4	Tofacitinib 5 mg BID	318	1.21	0.09	317	-0.76	0.09
	Tofacitinib 10 mg BID	323	0.90	0.08	319	-1.09	0.09
	Etanercept 50 mg BIW	325	0.93	0.08	322	-0.73	0.08
	Placebo	100	1.64	0.20	99	-0.18	0.14
Week 12	Tofacitinib 5 mg BID	306	0.85	0.09	305	-1.10	0.11
	Tofacitinib 10 mg BID	305	0.48	0.06	301	-1.46	0.10
	Etanercept 50 mg BIW	307	0.52	0.07	305	-1.17	0.09
	Placebo	93	1.65	0.20	93	-0.20	0.15
Treatment Subscale Score							

Table 20. Descriptive Statistics of Dermatology Life Quality Index (DLQI) and Change From Baseline: 6 Sub-Scales During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
Baseline	Tofacitinib 5 mg BID	328	1.22	0.06			
	Tofacitinib 10 mg BID	327	1.24	0.06			
	Etanercept 50 mg BIW	332	1.23	0.06			
	Placebo	106	1.18	0.10			
Week 4	Tofacitinib 5 mg BID	318	0.76	0.05	317	-0.47	0.06
	Tofacitinib 10 mg BID	323	0.52	0.04	320	-0.72	0.06
	Etanercept 50 mg BIW	325	0.65	0.04	322	-0.58	0.06
	Placebo	100	1.02	0.11	99	-0.12	0.10
Week 12	Tofacitinib 5 mg BID	306	0.45	0.04	305	-0.75	0.06
	Tofacitinib 10 mg BID	305	0.31	0.03	302	-0.91	0.06
	Etanercept 50 mg BIW	307	0.33	0.04	305	-0.91	0.06
	Placebo	93	0.95	0.11	93	-0.24	0.10

BID = twice daily, BIW = twice weekly, DLQI = Dermatology Life Quality Index, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Proportion of Subjects in Each Treatment Group Achieving a 5-Point Improvement in Total DLQI Score (DLQI Success Rate)

Among subjects with DLQI ≥5 at Baseline, a statistically significant and clinically meaningful improvement (≥5 point reduction in DLQI total score compared to Baseline) was observed at Week 12 for all treatment groups, with the greatest improvements observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups. Compared to placebo, a statistically significantly greater percentage of subjects in each active treatment group achieved a DLQI reduction of ≥5 points from Baseline compared to placebo at each time point ($p<0.0001$) (Table 21).

Table 21. Proportion of Subjects Achieving Dermatology Life Quality Index (DLQI) ≥5 Points Reduction From Baseline Response at Weeks 4 and 12 (FAS Subjects With Baseline DLQI ≥5, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 4									
Tofacitinib 5 mg BID	279	170 (60.93)	2.92	24.35	6.07	12.45, 36.24	-0.42	4.12	-8.48, 7.65
Tofacitinib 10 mg BID	283	202 (71.38)	2.69	34.79	5.96	23.11, 46.47	10.03	3.95	2.28, 17.78
Etanercept 50 mg BIW	282	173 (61.35)	2.90	24.76	6.06	12.89, 36.64			
Placebo	82	30 (36.59)	5.32						
Week 12									
Tofacitinib 5 mg BID	267	191 (71.54)	2.76	35.64	6.09	23.70, 47.58	-9.81	3.65	-16.95, -2.66
Tofacitinib 10 mg BID	265	226 (85.28)	2.18	49.39	5.85	37.92, 60.85	3.94	3.22	-2.38, 10.26
Etanercept 50 mg BIW	268	218 (81.34)	2.38	45.45	5.93	33.82, 57.07			
Placebo	78	28 (35.90)	5.43						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, DLQI = Dermatology Life Quality Index, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

Proportion of Subjects in Each Treatment Group Achieving a DLQI Score of '0' or '1'

At Baseline, <4% of subjects in all treatment groups had a DLQI total score 0 to 1, representing no effect of their skin disease on quality of life. The percentage of subjects achieving DLQI ≤1 response (among FAS subjects with Baseline DLQI >1, observed case) was highest at Week 12, with the greatest improvements observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups (51.4% and 47.2% of subjects, respectively) and tofacitinib 5 mg BID group (33.2% of subjects) compared to placebo (8.9% of subjects) (Table 22).

Table 22. Proportion of Subjects Achieving Dermatology Life Quality Index (DLQI) ≤1 Response at Weeks 4 and 12 (FAS Subjects With Baseline DLQI >1, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 4									
Tofacitinib 5 mg BID	306	40 (13.07)	1.93	5.70	3.30	-0.77, 12.17	-2.43	2.80	-7.93, 3.06
Tofacitinib 10 mg BID	312	68 (21.79)	2.34	14.43	3.56	7.46, 21.40	6.29	3.10	0.21, 12.36
Etanercept 50 mg BIW	316	49 (15.51)	2.04	8.14	3.37	1.54, 14.74			
Placebo	95	7 (7.37)	2.68						
Week 12									
Tofacitinib 5 mg BID	295	98 (33.22)	2.74	24.33	4.06	16.37, 32.30	-13.96	3.97	-21.75, -6.17
Tofacitinib 10 mg BID	294	151 (51.36)	2.91	42.47	4.18	34.27, 50.67	4.18	4.10	-3.84, 12.21
Etanercept 50 mg BIW	301	142 (47.18)	2.88	38.29	4.16	30.14, 46.43			
Placebo	90	8 (8.89)	3.00						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, DLQI = Dermatology Life Quality Index, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

The Actual and Change From Baseline on the SF-36 Mental Component Summary (MCS), Physical Component Summary (PCS), and 9 Domain Scores (Including the TR Scale Score) at Various Time Points Through Week 12

Descriptive statistics for SF-36 during the 12-week double-blind treatment and changes from Baseline in SF-36 scores at Week 12 are presented in Table 23.

Mean Baseline scores for the physical component score (PCS) and mental component score (MCS) were similar for all treatment groups. For the PCS, mean Baseline scores were 47.4 for the tofacitinib 5 mg BID group, 48.3 for the tofacitinib 10 mg BID group, 47.5 for the etanercept 50 mg BIW group, and 46.8 for the placebo group. For the MCS, mean Baseline scores were 42.0 for the tofacitinib 5 mg BID group, 41.2 for the tofacitinib 10 mg BID group, 42.0 for the etanercept 50 mg BIW group, and 39.8 for the placebo group; indicating a substantial burden at Baseline.

Table 23. Descriptive Statistics of Short Form 36 (SF-36) Physical and Mental Health Scores at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
Physical Health Score							
Baseline	Tofacitinib 5 mg BID	327	47.4	0.5			
	Tofacitinib 10 mg BID	327	48.3	0.5			
	Etanercept 50 mg BIW	327	47.5	0.5			
	Placebo	105	46.8	1.0			
Week 12	Tofacitinib 5 mg BID	303	51.7	0.5	301	4.1	0.4
	Tofacitinib 10 mg BID	304	53.6	0.4	302	5.0	0.5
	Etanercept 50 mg BIW	307	52.5	0.5	301	5.2	0.5
	Placebo	95	47.8	1.0	93	0.8	0.7
Mental Health Score							
Baseline	Tofacitinib 5 mg BID	327	42.0	0.6			
	Tofacitinib 10 mg BID	327	41.2	0.6			
	Etanercept 50 mg BIW	327	42.0	0.7			
	Placebo	105	39.8	1.2			
Week 12	Tofacitinib 5 mg BID	303	47.0	0.6	301	5.0	0.6
	Tofacitinib 10 mg BID	304	49.3	0.5	302	7.6	0.6
	Etanercept 50 mg BIW	307	47.8	0.6	301	5.8	0.6
	Placebo	95	41.7	1.3	93	1.5	1.1

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Descriptive statistics of SF-36 at Baseline and Week 12 and changes from Baseline at Week 12 for the 9 subscale scores are presented in Table 24.

Statistically significant improvements in subjects' health status were observed for all 9 of the SF-36 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health [>45], and health transition [<3]) for subjects in all active treatment groups at Week 12 compared to placebo ($p \leq 0.0005$), with a slightly greater mean change from Baseline observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups.

Table 24. Descriptive Statistics of Short Form 36 (SF-36): 9 Domains (PF, RP, BP, GH; VT, SF, RE, MH; TR) at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
Physical Functioning (PF)							
Baseline	Tofacitinib 5 mg BID	328	48.3	0.5			
	Tofacitinib 10 mg BID	328	49.0	0.5			
	Etanercept 50 mg BIW	330	48.6	0.5			
	Placebo	106	46.7	1.1			
Week 12	Tofacitinib 5 mg BID	306	51.9	0.5	305	3.5	0.4
	Tofacitinib 10 mg BID	305	53.1	0.4	304	3.7	0.4
	Etanercept 50 mg BIW	308	52.2	0.4	304	3.7	0.5
	Placebo	95	48.1	1.1	94	1.1	0.8
Role-Physical (RP)							
Baseline	Tofacitinib 5 mg BID	328	45.4	0.6			
	Tofacitinib 10 mg BID	328	45.9	0.6			
	Etanercept 50 mg BIW	330	45.5	0.6			
	Placebo	106	44.4	1.1			
Week 12	Tofacitinib 5 mg BID	307	50.5	0.5	306	5.1	0.5
	Tofacitinib 10 mg BID	305	52.5	0.4	304	6.3	0.6
	Etanercept 50 mg BIW	308	51.2	0.5	304	6.1	0.5
	Placebo	95	46.1	1.1	94	1.3	0.9
Bodily Pain (BP)							
Baseline	Tofacitinib 5 mg BID	328	44.5	0.7			
	Tofacitinib 10 mg BID	329	45.6	0.7			
	Etanercept 50 mg BIW	331	44.0	0.7			
	Placebo	107	43.6	1.2			
Week 12	Tofacitinib 5 mg BID	306	51.7	0.6	305	7.0	0.7
	Tofacitinib 10 mg BID	305	54.6	0.5	304	8.5	0.6
	Etanercept 50 mg BIW	307	52.4	0.6	304	8.6	0.7
	Placebo	95	45.7	1.3	95	1.6	1.0
General Health (GH)							
Baseline	Tofacitinib 5 mg BID	328	43.4	0.5			
	Tofacitinib 10 mg BID	328	42.8	0.5			
	Etanercept 50 mg BIW	330	43.5	0.6			
	Placebo	106	42.4	1.0			
Week 12	Tofacitinib 5 mg BID	305	46.2	0.5	304	2.5	0.5

Table 24. Descriptive Statistics of Short Form 36 (SF-36): 9 Domains (PF, RP, BP, GH; VT, SF, RE, MH; TR) at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
	Tofacitinib 10 mg BID	304	48.5	0.5	302	5.5	0.5
	Etanercept 50 mg BIW	308	47.9	0.5	304	4.4	0.5
	Placebo	95	42.6	1.0	94	0.2	0.8
Vitality (VT)							
Baseline	Tofacitinib 5 mg BID	328	47.9	0.5			
	Tofacitinib 10 mg BID	329	48.5	0.6			
	Etanercept 50 mg BIW	331	48.3	0.5			
	Placebo	107	46.5	1.0			
Week 12	Tofacitinib 5 mg BID	306	52.4	0.5	305	4.2	0.5
	Tofacitinib 10 mg BID	305	54.4	0.5	304	5.4	0.5
	Etanercept 50 mg BIW	307	52.9	0.5	304	4.6	0.5
	Placebo	95	47.9	1.1	95	1.3	0.9
Social Functioning (SF)							
Baseline	Tofacitinib 5 mg BID	328	41.6	0.6			
	Tofacitinib 10 mg BID	329	41.1	0.6			
	Etanercept 50 mg BIW	331	42.3	0.7			
	Placebo	107	40.7	1.2			
Week 12	Tofacitinib 5 mg BID	306	47.8	0.6	305	6.0	0.7
	Tofacitinib 10 mg BID	305	50.6	0.5	304	9.2	0.6
	Etanercept 50 mg BIW	307	49.3	0.5	304	7.3	0.6
	Placebo	95	42.0	1.2	95	0.7	1.1
Role-Emotional (RE)							
Baseline	Tofacitinib 5 mg BID	327	43.2	0.7			
	Tofacitinib 10 mg BID	328	42.4	0.7			
	Etanercept 50 mg BIW	330	43.1	0.7			
	Placebo	106	40.4	1.3			
Week 12	Tofacitinib 5 mg BID	307	48.6	0.5	305	5.4	0.6
	Tofacitinib 10 mg BID	305	50.2	0.5	304	7.2	0.6
	Etanercept 50 mg BIW	308	48.6	0.6	304	5.8	0.7
	Placebo	95	43.3	1.4	94	2.3	1.2
Mental Health (MH)							
Baseline	Tofacitinib 5 mg BID	328	42.0	0.6			
	Tofacitinib 10 mg BID	329	41.5	0.6			

Table 24. Descriptive Statistics of Short Form 36 (SF-36): 9 Domains (PF, RP, BP, GH; VT, SF, RE, MH; TR) at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
	Etanercept 50 mg BIW	331	41.7	0.7			
	Placebo	107	39.5	1.2			
Week 12	Tofacitinib 5 mg BID	306	46.6	0.6	305	4.5	0.6
	Tofacitinib 10 mg BID	305	48.9	0.5	304	7.0	0.6
	Etanercept 50 mg BIW	307	47.5	0.6	304	5.9	0.6
	Placebo	95	41.4	1.2	95	1.4	1.1
Health Transition (TR) Score							
Baseline	Tofacitinib 5 mg BID	328	3.2	0.0			
	Tofacitinib 10 mg BID	328	3.2	0.0			
	Etanercept 50 mg BIW	332	3.1	0.0			
	Placebo	107	3.2	0.1			
Week 12	Tofacitinib 5 mg BID	307	2.6	0.0	306	-0.5	0.1
	Tofacitinib 10 mg BID	305	2.6	0.0	303	-0.6	0.1
	Etanercept 50 mg BIW	308	2.5	0.0	306	-0.6	0.1
	Placebo	95	3.0	0.1	95	-0.2	0.1

BID = twice daily, BIW = twice weekly, BP = bodily pain, FAS = Full Analysis Set, GH = general health, MH = mental health, N = number of subjects, PF = physical functioning, RE = role-emotional, RP = role-physical, SE = standard error, SF = social functioning, TR = health transition, VT = vitality.

Proportion of Subjects in Each Treatment Group in Each PtGA Category at Various Time Points Through Week 12

Descriptive statistics for PtGA during the 12-week double-blind treatment are presented in Table 25. At Baseline the majority of subjects in each treatment group (≥60%) had a PtGA score corresponding to "severe" disease; no subjects had a PtGA of "clear" and only 2 subjects (1 in the tofacitinib 10 mg BID and etanercept 50 mg BIW group, respectively) had a PtGA response of "almost clear" at Baseline.

The proportion of subjects achieving a PtGA of "clear" or "almost clear" during the 12-week double-blind treatment period is presented in Table 26.

The percentage of subjects with a PtGA response of "clear" or "almost clear" increased at each time point in all active treatment groups. In addition, the number of subjects reporting "severe" disease had notably decreased in all active treatment groups from Baseline (211 [64.3%], 223 [68.0%] and 221 [67.0%] in the tofacitinib 5 mg BID, tofacitinib 10 mg BID and etanercept 50 mg BIW groups, respectively) to Week 12 (42 [13.7%], 21 [6.9%] and 18 [5.8%] in the tofacitinib 5 mg BID, tofacitinib 10 mg BID and etanercept 50 mg BIW groups, respectively) compared to a smaller proportional change in the placebo group (Baseline: 78 [72.9%]; Week 12: 51 [53.7%]).

Table 25. Descriptive Statistics of Patient Global Assessment (PtGA) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	PGA Category	Tofacitinib 5 mg BID n (%)	Tofacitinib 10 mg BID n (%)	Etanercept 50 mg BIW n (%)	Placebo n (%)
Baseline	Clear (0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Almost clear (1)	0 (0.0)	1 (0.3)	1 (0.3)	0 (0.0)
	Mild (2)	11 (3.4)	5 (1.5)	14 (4.2)	4 (3.7)
	Moderate (3)	106 (32.3)	99 (30.2)	94 (28.5)	25 (23.4)
	Severe (4)	211 (64.3)	223 (68.0)	221 (67.0)	78 (72.9)
	N (total)	328	328	330	107
Week 2	Clear (0)	1 (0.3)	0 (0.0)	1 (0.3)	0 (0.0)
	Almost clear (1)	4 (1.2)	14 (4.3)	4 (1.2)	1 (0.9)
	Mild (2)	43 (13.3)	48 (14.9)	39 (11.8)	3 (2.8)
	Moderate (3)	160 (49.4)	175 (54.3)	172 (52.0)	41 (38.7)
	Severe (4)	116 (35.8)	85 (26.4)	115 (34.7)	61 (57.5)
	N (total)	324	322	331	106
Week 4	Clear (0)	1 (0.3)	2 (0.6)	1 (0.3)	0 (0.0)
	Almost clear (1)	22 (6.9)	55 (17.0)	30 (9.3)	0 (0.0)
	Mild (2)	69 (21.6)	99 (30.7)	86 (26.5)	5 (5.0)
	Moderate (3)	149 (46.7)	119 (36.8)	141 (43.5)	35 (35.0)
	Severe (4)	78 (24.5)	48 (14.9)	66 (20.4)	60 (60.0)
	N (total)	319	323	324	100
Week 8	Clear (0)	9 (2.9)	15 (4.7)	11 (3.5)	0 (0.0)
	Almost clear (1)	53 (16.9)	121 (38.2)	94 (29.8)	4 (4.1)
	Mild (2)	105 (33.5)	86 (27.1)	104 (33.0)	7 (7.2)
	Moderate (3)	98 (31.3)	70 (22.1)	78 (24.8)	37 (38.1)
	Severe (4)	48 (15.3)	25 (7.9)	28 (8.9)	49 (50.5)
	N (total)	313	317	315	97
Week 12	Clear (0)	20 (6.5)	39 (12.8)	26 (8.4)	0 (0.0)
	Almost clear (1)	80 (26.1)	132 (43.4)	138 (44.7)	1 (1.1)
	Mild (2)	73 (23.9)	56 (18.4)	72 (23.3)	10 (10.5)
	Moderate (3)	91 (29.7)	56 (18.4)	55 (17.8)	33 (34.7)
	Severe (4)	42 (13.7)	21 (6.9)	18 (5.8)	51 (53.7)
	N (total)	306	304	309	95

Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly; FAS = Full Analysis Set.

Table 26. Proportion of Subjects Achieving Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit / Treatment	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 2									
Tofacitinib 5 mg BID	324	5 (1.54)	0.68	0.60	1.16	-1.68, 2.88	0.03	0.96	-1.85, 1.91
Tofacitinib 10 mg BID	322	14 (4.35)	1.14	3.40	1.47	0.52, 6.29	2.84	1.32	0.25, 5.42
Etanercept 50 mg BIW	331	5 (1.51)	0.67	0.57	1.15	-1.69, 2.83			
Placebo	106	1 (0.94)	0.94						
Week 4									
Tofacitinib 5 mg BID	319	23 (7.21)	1.45	7.21	1.45	4.37, 10.05	-2.36	2.18	-6.64, 1.92
Tofacitinib 10 mg BID	323	57 (17.65)	2.12	17.65	2.12	13.49, 21.80	8.08	2.68	2.83, 13.33
Etanercept 50 mg BIW	324	31 (9.57)	1.63	9.57	1.63	6.36, 12.77			
Placebo	100	0 (0.00)	0.00						
Week 8									
Tofacitinib 5 mg BID	313	62 (19.81)	2.25	15.68	3.03	9.76, 21.61	-13.53	3.48	-20.35, -6.70
Tofacitinib 10 mg BID	317	136 (42.90)	2.78	38.78	3.44	32.04, 45.51	9.57	3.84	2.03, 17.10
Etanercept 50 mg BIW	315	105 (33.33)	2.66	29.21	3.34	22.67, 35.75			
Placebo	97	4 (4.12)	2.02						
Week 12									
Tofacitinib 5 mg BID	306	100 (32.68)	2.68	31.63	2.88	25.99, 37.27	-20.39	3.91	-28.05, -12.74
Tofacitinib 10 mg BID	304	171 (56.25)	2.85	55.20	3.03	49.26, 61.14	3.18	4.02	-4.70, 11.05
Etanercept 50 mg BIW	309	164 (53.07)	2.84	52.02	3.03	46.09, 57.95			
Placebo	95	1 (1.05)	1.05						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

Proportion of Subjects in Each Treatment Group in Each PSSM Category at Week 12

Descriptive statistics for PSSM indicating overall subject satisfaction with the study treatment at Week 12 are presented in Table 27.

The percentage of subjects with a PSSM response of "very satisfied" or "somewhat satisfied" at Week 12 is presented in Table 28.

Table 27. Descriptive Statistics of Patient Satisfaction With Study Medication (PSSM) Score at Week 12 (FAS, Observed Case)

Visit	PSSM Category	Tofacitinib 5 mg BID n (%)	Tofacitinib 10 mg BID n (%)	Etanercept 50 mg BIW n (%)	Placebo n (%)
Week 12	Very satisfied	135 (44.0)	209 (68.5)	191 (62.4)	15 (15.8)
	Somewhat satisfied	83 (27.0)	53 (17.4)	72 (23.5)	15 (15.8)
	Slightly satisfied	36 (11.7)	16 (5.2)	22 (7.2)	11 (11.6)
	Neither satisfied nor dissatisfaction	14 (4.6)	7 (2.3)	6 (2.0)	11 (11.6)
	Slightly dissatisfied	8 (2.6)	5 (1.6)	6 (2.0)	4 (4.2)
	Somewhat dissatisfied	14 (4.6)	9 (3.0)	6 (2.0)	12 (12.6)
	Very dissatisfied	17 (5.5)	6 (2.0)	3 (1.0)	27 (28.4)
	N (total)	307	305	306	95

BID = twice daily, BIW = twice weekly, FAS = full analysis set, n = number of subjects.

Table 28. Proportion of Subjects Achieving Patient Satisfaction With Study Medication (PSSM) Response of "Very Satisfied" or "Somewhat Satisfied at Week 12 (FAS, Observed Case)

	Response			Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 12									
Tofacitinib 5 mg BID	307	218 (71.01)	2.59	39.43	5.43	28.79, 50.07	-14.94	3.26	-21.34, -8.54
Tofacitinib 10 mg BID	305	262 (85.90)	1.99	54.32	5.17	44.19, 64.45	-0.05	2.81	-5.56, 5.47
Etanercept 50 mg BIW	306	263 (85.95)	1.99	54.37	5.17	44.24, 64.49			
Placebo	95	30 (31.58)	4.77						

95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

The Actual and Change From Baseline in EQ-5D Through Week 12

Descriptive statistics of actual and change from Baseline in EQ-5D indicating overall subject impact on quality of life in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression are presented in Table 29. Similar Baseline scores in EQ-5D were observed for all treatment groups (mean: 0.7), with a slightly lower score for the placebo group (mean: 0.6). These scores indicate a considerable level of burden at Baseline for the study population.

All active treatment groups demonstrated statistically significant improvements compared to placebo at Week 12 on the EQ-5D Utility score, with a greater difference compared to placebo observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups (Table 30).

Descriptive statistics of actual and change from Baseline in EQ-5D Visual Analog Scale (VAS) at Baseline and Week 12 are presented in Table 31. Similar mean Baseline scores in EQ-5D were observed for the tofacitinib 5 mg BID and 10 mg BID groups and placebo (mean: 63.3 for tofacitinib 5 mg BID and 10 mg BID groups; and 60.5 for the placebo group); however, the mean score was lower at Baseline for the etanercept 50 mg BIW treatment group (mean: 64.2).

Descriptive statistics of EQ-5D at Baseline and Week 12 and change from Baseline at Week 12 for the 5 domains are presented in Table 32. The greatest mean change from Baseline was observed for the pain/discomfort domain (-0.4 to -0.5, indicating a large improvement) for all active treatment groups.

Table 29. Descriptive Statistics of Actual and Change From Baseline Euro-Qol 5 Dimensions (EQ-5D) Utility Score During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Baseline	Tofacitinib 5 mg BID	325	0.7	0.0
	Tofacitinib 10 mg BID	326	0.7	0.0
	Etanercept 50 mg BIW	330	0.7	0.0
	Placebo	104	0.6	0.0
Week 12	Tofacitinib 5 mg BID	305	0.8	0.0
	Tofacitinib 10 mg BID	304	0.9	0.0
	Etanercept 50 mg BIW	307	0.9	0.0
	Placebo	95	0.7	0.0
Week 12 - change from Baseline	Tofacitinib 5 mg BID	301	0.1	0.0
	Tofacitinib 10 mg BID	300	0.2	0.0
	Etanercept 50 mg BIW	303	0.2	0.0
	Placebo	92	0.0	0.0

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Table 30. Least-Square Mean of Change From Baseline Euro-Qol 5 Dimensions (EQ-5D) Utility Score at Week 12 - Statistical Testing From Analysis of Covariance Model (FAS, Observed Case)

Visit / Treatment				Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	LS Mean	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 12									
Tofacitinib 5 mg BID	301	0.14	0.011	0.11	0.023	0.07, 0.16	-0.05	0.016	-0.08, -0.01
Tofacitinib 10 mg BID	300	0.21	0.011	0.18	0.023	0.13, 0.22	0.02	0.016	-0.01, 0.05
Etanercept 50 mg BIW	303	0.19	0.011	0.16	0.023	0.11, 0.20			
Placebo	92	0.03	0.021						

Baseline EQ-5D score and treatment were included in the model
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, LS = least square, N = number of subjects, SE = standard error.

Table 31. Descriptive Statistics of Actual and Change From Baseline Euro-Qol 5 Dimensions (EQ-5D) Visual Analogue Scale During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Baseline	Tofacitinib 5 mg BID	315	63.3	1.3
	Tofacitinib 10 mg BID	318	63.3	1.3
	Etanercept 50 mg BIW	312	64.2	1.3
	Placebo	100	60.5	2.7
Week 12	Tofacitinib 5 mg BID	298	75.3	1.1
	Tofacitinib 10 mg BID	294	81.1	1.0
	Etanercept 50 mg BIW	297	80.0	1.0
	Placebo	91	65.1	2.6
Week 12 - change from Baseline	Tofacitinib 5 mg BID	289	11.6	1.4
	Tofacitinib 10 mg BID	288	16.6	1.5
	Etanercept 50 mg BIW	285	15.7	1.4
	Placebo	88	3.0	2.4

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Table 32. Descriptive Statistics of Euro-Qol 5 Dimensions (EQ-5D): 5 Domains at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
Mobility							
Baseline	Tofacitinib 5 mg BID	326	1.3	0.0			
	Tofacitinib 10 mg BID	327	1.3	0.0			
	Etanercept 50 mg BIW	330	1.3	0.0			
	Placebo	104	1.3	0.0			
Week 12	Tofacitinib 5 mg BID	306	1.2	0.0	303	-0.1	0.0
	Tofacitinib 10 mg BID	304	1.1	0.0	301	-0.1	0.0
	Etanercept 50 mg BIW	307	1.2	0.0	303	-0.1	0.0
	Placebo	95	1.3	0.1	92	0.0	0.0
Self-Care							
Baseline	Tofacitinib 5 mg BID	327	1.2	0.0			
	Tofacitinib 10 mg BID	327	1.1	0.0			
	Etanercept 50 mg BIW	330	1.1	0.0			
	Placebo	104	1.2	0.0			
Week 12	Tofacitinib 5 mg BID	306	1.1	0.0	304	-0.1	0.0
	Tofacitinib 10 mg BID	304	1.0	0.0	301	-0.1	0.0
	Etanercept 50 mg BIW	307	1.1	0.0	303	-0.1	0.0
	Placebo	95	1.2	0.0	92	-0.1	0.0
Usual Activities							
Baseline	Tofacitinib 5 mg BID	327	1.4	0.0			
	Tofacitinib 10 mg BID	327	1.4	0.0			
	Etanercept 50 mg BIW	330	1.4	0.0			
	Placebo	104	1.5	0.1			
Week 12	Tofacitinib 5 mg BID	307	1.2	0.0	305	-0.3	0.0
	Tofacitinib 10 mg BID	304	1.1	0.0	301	-0.3	0.0
	Etanercept 50 mg BIW	307	1.2	0.0	303	-0.2	0.0
	Placebo	95	1.3	0.1	92	-0.1	0.1
Pain/Discomfort							
Baseline	Tofacitinib 5 mg BID	327	1.8	0.0			
	Tofacitinib 10 mg BID	328	1.8	0.0			
	Etanercept 50 mg BIW	330	1.9	0.0			
	Placebo	104	1.8	0.1			
Week 12	Tofacitinib 5 mg BID	307	1.5	0.0	305	-0.4	0.0

Table 32. Descriptive Statistics of Euro-Qol 5 Dimensions (EQ-5D): 5 Domains at Baseline and Week 12 and Change From Baseline at Week 12 (FAS, Observed Case)

Visit	Treatment	Actual Value			Change From Baseline		
		N	Mean	SE	N	Mean Change	SE
	Tofacitinib 10 mg BID	304	1.3	0.0	302	-0.5	0.0
	Etanercept 50 mg BIW	307	1.4	0.0	303	-0.5	0.0
	Placebo	95	1.7	0.1	92	-0.1	0.1
Anxiety/Depression							
Baseline	Tofacitinib 5 mg BID	326	1.6	0.0			
	Tofacitinib 10 mg BID	327	1.7	0.0			
	Etanercept 50 mg BIW	330	1.6	0.0			
	Placebo	104	1.7	0.1			
Week 12	Tofacitinib 5 mg BID	305	1.4	0.0	302	-0.2	0.0
	Tofacitinib 10 mg BID	304	1.3	0.0	301	-0.4	0.0
	Etanercept 50 mg BIW	307	1.3	0.0	303	-0.3	0.0
	Placebo	95	1.5	0.1	92	-0.1	0.1

BID = twice daily, BIW = twice weekly, FAS = Full Analysis Set, N = number of subjects, SE = standard error.

Proportion of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment

A summary of healthcare professional interactions at Baseline and Week 12 are presented in Table 33. At Baseline, the most common interaction for subjects was with a Dermatologist (approximately 10% of events), with less frequent interactions with other health practitioners among subjects (≤2.5% of events per category). At Week 12, in all treatment groups, most interactions occurred with "General Practitioner/Primary Care Physician/Family Medicine Physician" (≤10% of subjects) and, in the active treatment groups with "other" healthcare professionals. Of the 366 interactions with a healthcare professional, 66 (44.2%) of events in the tofacitinib 5 mg BID group, 21 (26.5%) of events in the tofacitinib 10 mg BID group, 25 (21.7%) of events in the etanercept 50 mg BIW group, and 16 (69.5%) in the placebo group were for psoriasis-related reasons.

Table 33. Summary of Interaction With Healthcare Profession at Baseline and Week 12 (FAS, Observed Case)

Visit	Healthcare Professional	Tofacitinib 5 mg BID (N=329) n (%)	Tofacitinib 10 mg BID (N=330) n (%)	Etanercept 50 mg BIW (N=335) n (%)	Placebo (N = 107) n (%)
Baseline	(Number of subjects that answered Ps-HCRU at Baseline)	230	220	224	77
	General Practitioner/Primary Care Physician/Family Medicine Physician	2 (0.8)	2 (0.9)	3 (1.3)	2 (2.5)
	Dermatologist	16 (6.9)	10 (4.5)	17 (7.5)	8 (10.3)
	Rheumatologist	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Cardiologist	1 (0.4)	1 (0.4)	1 (0.4)	2 (2.5)
	Gastroenterologist	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)
	Psychiatrist	0 (0.0)	1 (0.4)	0 (0.0)	1 (1.2)
	Surgeon	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)
	Nurse	3 (1.3)	3 (1.3)	2 (0.8)	2 (2.5)
	Other	5 (2.1)	2 (0.9)	0 (0.0)	1 (1.2)
Week 12	(Number of Subjects that answered Ps-HCRU up to Week 12)	255	251	261	79
	General Practitioner/Primary Care Physician/Family Medicine Physician	26 (10.1)	17 (6.7)	22 (8.4)	7 (8.8)
	Dermatologist	21 (8.2)	11 (4.3)	15 (5.7)	6 (7.5)
	Rheumatologist	2 (0.7)	3 (1.1)	2 (0.7)	0 (0.0)
	Cardiologist	4 (1.5)	5 (1.9)	7 (2.6)	1 (1.2)
	Gastroenterologist	3 (1.1)	4 (1.5)	4 (1.5)	0 (0.0)
	Psychiatrist	0 (0.0)	2 (0.7)	4 (1.5)	0 (0.0)
	Surgeon	1 (0.3)	1 (0.3)	0 (0.0)	0 (0.0)
	Nurse	3 (1.1)	5 (1.9)	7 (2.6)	0 (0.0)
	Other	22 (8.6)	13 (5.1)	18 (6.8)	2 (2.5)

BID = twice daily, BIW = bi-weekly, N = number of subjects, n = number of subjects meeting prespecified criteria.

Proportion of Subjects in Each Treatment Group Reporting Healthcare Resource use Events at Various Time Points Through Week 12

The proportion of subjects reporting healthcare resource use events due to psoriasis at Week 12 is presented in Table 34.

Table 34. Proportion of Subjects Reporting Healthcare Resource Use Events at Week 12 (FAS, Observed Case)

Visit / Treatment				Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
	N	n (%)	SE	Diff	SE	95% CI	Diff	SE	95% CI
Week 12									
Tofacitinib 5 mg BID	230	24 (10.43)	2.02	1.98	3.87	-5.60, 9.57	0.35	2.81	-5.15, 5.85
Tofacitinib 10 mg BID	225	22 (9.78)	1.98	1.33	3.85	-6.22, 8.87	-0.31	2.78	-5.76, 5.14
Etanercept 50 mg BIW	238	24 (10.08)	1.95	1.63	3.83	-5.88, 9.15			
Placebo	71	6 (8.45)	3.30						

n = Subjects answering Yes to the respective questions about the events.
95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

Frequency of Work Impacted Events in Each Treatment Group at Various Time Points Through Week 12

A summary of the impact on subjects' ability to work is presented in Table 35. At Baseline, the majority of subjects were employed (156 [67.8%] subjects in the tofacitinib 5 mg BID group, 156 [71.2%] subjects in the tofacitinib 10 mg BID group, 162 [72.3%] subjects in the etanercept 50 mg BIW group, and 55 [71.4%] subjects in the placebo group) and of those currently employed, 18.3% to 23.4% were absent or on sick leave at the time of reporting due to psoriasis. Similar findings were observed at Week 12 for the percentage of subjects reporting employment (68.1% to 73.8%); however, a slight improvement was observed in the number reporting being absent or on sick leave due to psoriasis (13.2% to 17.4%).

Table 35. Summary of Impact of Psoriasis on Work at Baseline and Week 12 (FAS, Observed Case)

Visit	Currently Employed		Tofacitinib 5 mg BID n (%)	Tofacitinib 10 mg BID n (%)	Etanercept 50 mg BIW n (%)	Placebo n (%)
Baseline	Yes		156 (67.8)	156 (71.2)	162 (72.3)	55 (71.4)
		If you are currently employed, were you absent or on sick leave from work due to psoriasis today?				
		Yes	42 (18.3)	46 (21.0)	50 (22.3)	18 (23.4)
		No	111 (48.3)	109 (49.8)	110 (49.1)	36 (46.8)
	No		74 (32.2)	63 (28.8)	62 (27.7)	22 (28.6)
		Are you unemployed due to your psoriasis?				
		Yes	22 (9.6)	16 (7.3)	14 (6.3)	2 (2.6)
		No	50 (21.7)	45 (20.5)	46 (20.5)	20 (26.0)
Week 12	Yes		157 (69.2)	166 (73.8)	163 (69.1)	47 (68.1)
		If you are currently employed, were you absent or on sick leave from work due to psoriasis today?				
		Yes	30 (13.2)	33 (14.7)	37 (15.7)	12 (17.4)
		No	126 (55.5)	128 (56.9)	125 (53.0)	35 (50.7)
	No		70 (30.8)	59 (26.2)	73 (30.9)	22 (31.9)
		Are you unemployed due to your psoriasis?				
		Yes	9 (4.0)	11 (4.9)	11 (4.7)	3 (4.3)
		No	59 (26.0)	47 (20.9)	58 (24.6)	18 (26.1)

Percentages were based on the number of subjects reporting their employment status (Yes/No).
Baseline is defined as the last observation up to first dosing date.

Proportion of Subjects in Each Treatment Group Reporting Work Impacted Events at Various Time Points Through Week 12

The proportion of subjects in each treatment group reporting work impacted events at various time points through Week 12 are summarized in Table 36.

Table 36. Proportion of Subjects Reporting Work Impacted Events due to Psoriasis at Week 12 (FAS, Observed Case)

Visit / Treatment	N	N (%)	SE	Difference From Placebo (Active - Placebo)			Difference From Etanercept (Active - Etanercept)		
				Diff	SE	95% CI	Diff	SE	95% CI
Week 12									
Tofacitinib 5 mg BID	158	60 (37.97)	3.86	-18.28	8.13	-34.22, -2.33	3.83	5.35	-6.66, 14.31
Tofacitinib 10 mg BID	164	50 (30.49)	3.59	-25.76	8.01	-41.47, -10.06	-3.66	5.16	-13.77, 6.46
Etanercept 50 mg BIW	164	56 (34.15)	3.70	-22.10	8.06	-37.90, -6.30			
Placebo	48	27 (56.25)	7.16						

n = subjects answering Yes to the respective questions about the events.
95% confidence interval is constructed using the normal approximation to the binomial distribution of 2-sample proportion.
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, CI = confidence interval, Diff = difference, FAS = Full Analysis Set, N = number of subjects, n = number of subjects meeting prespecified criteria, SE = standard error.

The Actual and Change From Baseline on the PQOL-12 at Various Time Points Through Week 12

Descriptive statistics of actual and change from Baseline in PQoL-12 at Baseline and Week 12 are presented in Table 37.

At Baseline, similar results were obtained for PQoL-12 scores across treatment groups (tofacitinib 5 mg BID: 75.4; tofacitinib 10 mg BID: 77.0; etanercept 50 mg BIW: 75.7; and placebo: 74.9), representing a moderately large impact on psoriasis-related quality of life. A decrease (improvement) in PQoL-12 score was observed for all active treatment groups compared to Baseline, with the greatest change observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups.

Table 37. Descriptive Statistics of Actual and Change From Baseline Psoriasis Quality of Life 12 (PQOL-12) During the 12-Week Double-Blind Treatment (FAS, Observed Case)

Visit	Treatment	N	Mean	SE
Baseline	Tofacitinib 5 mg BID	323	75.4	1.5
	Tofacitinib 10 mg BID	326	77.0	1.5
	Etanercept 50 mg BIW	331	75.7	1.5
	Placebo	105	74.9	2.9
Week 12	Tofacitinib 5 mg BID	303	40.0	1.8
	Tofacitinib 10 mg BID	303	29.2	1.6
	Etanercept 50 mg BIW	306	31.0	1.7
	Placebo	92	65.5	3.5
Week 12 - change from Baseline	Tofacitinib 5 mg BID	299	-35.2	1.9
	Tofacitinib 10 mg BID	299	-47.9	1.8
	Etanercept 50 mg BIW	303	-44.3	1.8
	Placebo	90	-9.6	2.6

BID = twice daily, BIW = twice weekly, N = number of subjects, PQOL-12 = Psoriasis Quality of Life 12, SE = standard error.

Safety Results:

Table 38 summarizes treatment-emergent non-serious AEs and Table 39 summarizes treatment-emergent serious AEs.

Table 38. Treatment-Emergent Non-Serious Adverse Events by System Organ Class and Preferred Term (All Causalities) Occurring in >5% of Subjects in Any Treatment Arm

Number (%) of Subjects With Adverse Events by: System Organ Class and MedDRA (v16.1) Preferred Term	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2
Evaluable for adverse events	329			330			335			107		
With adverse events	39 (11.9)			53 (16.1)			55 (16.4)			14 (13.1)		
General disorders and administration site conditions	0	0	0	1 (0.3)	1	1	18 (5.4)	34	33	0	0	0
Injection site erythema	0	0	0	1 (0.3)	1	1	18 (5.4)	34	33	0	0	0
Infections and infestations	21 (6.4)	22	8	30 (9.1)	34	18	25 (7.5)	31	17	10 (9.3)	11	5
Nasopharyngitis	21 (6.4)	22	8	30 (9.1)	34	18	25 (7.5)	31	17	10 (9.3)	11	5
Nervous system disorders	21 (6.4)	27	17	24 (7.3)	28	16	13 (3.9)	15	8	4 (3.7)	4	2
Headache	21 (6.4)	27	17	24 (7.3)	28	16	13 (3.9)	15	8	4 (3.7)	4	2

Except for 'n1' and 'n2' Subjects are only counted once per treatment for each row.
n = the number of subjects in this reporting group affected by any occurrence of this adverse event, all causalities.
n1 = the number of occurrences of treatment emergent all causalities adverse events.
n2 = the number of occurrences of treatment emergent causally related to treatment adverse events.
Includes data up to 999 days after last dose of study drug.
BID = twice daily, BIW = bi-weekly, MedDRA = Medical Dictionary for Regulatory Activities, v = version.

Table 39. Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term

Number (%) of Subjects With Adverse Events by: System Organ Class and MedDRA (v16.1) Preferred Term	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2
Evaluable for adverse events	329			330			335			107		
With adverse events	7 (2.1)			5 (1.5)			7 (2.1)			2 (1.9)		
Cardiac disorders	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Myocardial infarction	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Eye disorders	0	0	0	0	0	0	1 (0.3)	1	1	0	0	0
Uveitis	0	0	0	0	0	0	1 (0.3)	1	1	0	0	0
General disorders and administration site conditions	0	0	0	0	0	0	0	0	0	1 (0.9)	1	1
Oedema peripheral	0	0	0	0	0	0	0	0	0	1 (0.9)	1	1
Hepatobiliary disorders	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Jaundice	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Infections and infestations	2 (0.6)	2	2	2 (0.6)	2	0	2 (0.6)	2	1	0	0	0
Bronchitis	0	0	0	0	0	0	1 (0.3)	1	1	0	0	0
Diverticulitis	1 (0.3)	1	1	0	0	0	0	0	0	0	0	0
Extradural abscess	1 (0.3)	1	1	0	0	0	0	0	0	0	0	0
Paronychia	0	0	0	1 (0.3)	1	0	0	0	0	0	0	0
Perineal abscess	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Pneumonia	0	0	0	1 (0.3)	1	0	0	0	0	0	0	0
Injury, poisoning and procedural complications	1 (0.3)	5	0	0	0	0	1 (0.3)	1	0	0	0	0
Foot fracture	1 (0.3)	2	0	0	0	0	0	0	0	0	0	0
Lower limb fracture	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Poisoning	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Rib fracture	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Thoracic vertebral fracture	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Neoplasms benign, malignant and unspecified (incl cycts and polyps)	0	0	0	1 (0.3)	1	0	0	0	0	0	0	0
Gastric cancer	0	0	0	1 (0.3)	1	0	0	0	0	0	0	0
Nervous system disorders	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Ischaemic cerebral infarction	0	0	0	0	0	0	1 (0.3)	1	0	0	0	0
Psychiatric disorders	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Depression	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Renal and urinary disorders	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Renal colic	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Respiratory, thoracic and mediastinal disorders	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0

Table 39. Treatment-Emergent Serious Adverse Events by System Organ Class and Preferred Term

Number (%) of Subjects With Adverse Events by: System Organ Class and MedDRA (v16.1) Preferred Term	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2	n (%)	n1	n2
Epistaxis	1 (0.3)	1	0	0	0	0	0	0	0	0	0	0
Skin and subcutaneous tissue disorders	0	0	0	2 (0.6)	2	2	1 (0.3)	1	1	2 (1.9)	2	2
Psoriasis	0	0	0	2 (0.6)	2	2	1 (0.3)	1	1	2 (1.9)	2	2

Except for 'n1' and 'n2' Subjects are only counted once per treatment for each row.
n = the number of subjects in this reporting group affected by any occurrence of this adverse event, all causalities.
n1 = the number of occurrences of treatment emergent all causalities adverse events.
n2 = the number of occurrences of treatment emergent causally related to treatment adverse events.
Includes data up to 999 days after last dose of study drug.
BID = twice daily, BIW = bi-weekly, incl = inclusive, MedDRA = Medical Dictionary for Regulatory Activities, v = version.

Permanent Discontinuations due to Adverse Events

Few AEs that led to permanent discontinuation occurred in >1 subject in any treatment group. These were depression (2 [0.6%] subjects in the tofacitinib 10 mg BID group), drug hypersensitivity (2 [0.6%] subjects in the etanercept 50 mg BIW group) and psoriasis (2 [0.6%] subjects in the tofacitinib 10 mg BID group, 1 [0.3%] subject in the etanercept 50 mg BIW group and 4 [3.7%] subjects in the placebo group; there were no discontinuations due to psoriasis in the tofacitinib 5 mg BID group). There were no other notable trends across treatment groups. Discontinuations due to treatment-emergent AEs are summarized in Table 40.

Of the 32 AEs (28 subjects) that led to withdrawal, 25 AEs (in 23 subjects) were considered related to study treatment. The majority of these AEs were reported to have resolved.

Table 40. Discontinuations due to Treatment-Emergent Adverse Events

S.No.	System Organ Class	MedDRA Preferred Term	Treatment Phase	Study Start Day[a]/Study Stop Day[a]	Severity/Outcome	Action/Investigator Causality
Tofacitinib 5 mg BID						
1	Infections and Infestations	Influenza	Active	28/ongoing	Severe/Still present	Permanently discontinued/Study drug
2	Infections and Infestations	Extradural abscess	Active	16/233	Moderate/Resolved	Permanently discontinued/Study drug
3	Renal and urinary disorders	Renal colic	Active	57/58	Moderate/Resolved	Permanently discontinued/Other illness (nephrolithiasis)
Tofacitinib 10 mg BID						
1	Skin and subcutaneous tissue disorders	Psoriasis	Active	4/33	Severe/Resolved	Permanently discontinued/Study drug
2	Skin and subcutaneous tissue disorders	Dermatitis exfoliative	Active	23/48	Severe/Resolved	Permanently discontinued/Study drug
3	Vascular disorders	Flushing	Active	60/63	Mild/Resolved	Permanently discontinued/Study drug
4	Skin and subcutaneous tissue disorders	Psoriasis	Active	44/74	Moderate/Resolved	Permanently discontinued/Study drug
5	Gastrointestinal disorders	Diarrhoea	Active	16/40	Moderate/Resolved	Permanently discontinued/Study drug
6	Psychiatric disorders	Depression	Active	13/>13	Mild/Unknown	Permanently discontinued/Study drug
7	Investigations	Platelet count decreased	Active	85/92	Moderate/Resolved	Permanently discontinued/Other (present prior to starting study)
8	Investigations	Alanine aminotransferase increased	Active	-26/77	Mild/Resolved	Permanently discontinued/Other illness (by-pass surgery)
9	Psychiatric disorders	Depression	Active	7/ongoing	Moderate/Still present	Permanently discontinued/Study drug
10	Respiratory, thoracic and mediastinal disorders	Dyspnoea	Active	9/9	Mild/Resolved	Permanently discontinued/Study drug
11	Infections and Infestations	Paronychia	Active	49/106	Severe/Resolved	Permanently discontinued /Other (infection)
Etanercept 50 mg BIW						
1	Immune system disorders	Drug hypersensitivity	Active	4/36	Moderate/Resolved	Permanently discontinued/Study drug
2	Immune system disorders	Drug hypersensitivity	Active	18/43	Moderate/Resolved	Permanently discontinued/Study drug
3	General disorders and administration site conditions	Injection site urticaria	Active	11/>16	Moderate/Unknown	Permanently discontinued/Study drug
4	Skin and subcutaneous tissue disorders	Psoriasis	Active	12/24	Severe/Resolved	Permanently discontinued/Study drug
5	General disorders and administration site conditions	Granuloma	Active	-20/-20	Mild/Resolved	Permanently discontinued/Other (past – a lesion was present in chest X-ray)
6	Muskuloskeletal and connective tissue disorders	Myalgia	Active	8/70	Mild/Resolved	Permanently discontinued/Study drug
7	Gastrointestinal disorders	Diarrhoea	Active	58/62	Severe/Resolved	Permanently discontinued/Study drug
8	General disorders and administration site conditions	Injection site pain	Active	10/15	Moderate/Resolved	Permanently discontinued/Study drug
	General disorders and administration site conditions	Injection site swelling	Active	10/15	Moderate/Resolved	Permanently discontinued/Missing
9	Skin and subcutaneous tissue disorders	Skin mass	Active	15/56	Moderate/Resolved	Permanently discontinued/Study drug

Table 40. Discontinuations due to Treatment-Emergent Adverse Events

S.No.	System Organ Class	MedDRA Preferred Term	Treatment Phase	Study Start Day[a]/Study Stop Day[a]	Severity/Outcome	Action/Investigator Causality
10	Skin and subcutaneous tissue disorders	Urticaria	Active	11/20	Mild/Resolved	Permanently discontinued/Study drug
11	Eye disorders	Uveitis	Active	37/ongoing	Mild/Still present	Permanently discontinued/Study drug
12	Skin and subcutaneous tissue disorders	Perineal abscess	Active	3/44	Moderate/Resolved	Permanently discontinued/Disease under study
Placebo						
1	Skin and subcutaneous tissue disorders	Psoriasis	Active	11/31	Severe/Resolved	Permanently discontinued/Study drug
2	Skin and subcutaneous tissue disorders	Psoriasis	Active	14/127	Moderate/Resolved	Permanently discontinued/Study drug
3	General disorders and administration site conditions	Oedema peripheral	Active	37/39	Severe/Resolved	Permanently discontinued/Study drug
	Skin and subcutaneous tissue disorders	Psoriasis	Active	37/39	Severe/Resolved	Permanently discontinued/Study drug
4	Skin and subcutaneous tissue disorders	Psoriasis	Active	29/53	Moderate/Resolved	Permanently discontinued/Study drug

One subject (platelet count decreased) in the tofacitinib 10 mg BID group, and one subject (granuloma) in the etanercept 50 mg BIW group, reported events that occurred prior to starting treatment.
BID = twice daily, BIW = bi-weekly, MedDRA = Medical Dictionary for Regulatory Activities.
a. Day relative to start of study treatment. First day of study treatment = Day 1.

Dose Reductions or Temporary Discontinuations due to Adverse Events

Dose modifications (ie, dose frequencies increased or reduced) were not permitted for this study. However, 2 subjects (1 each in the tofacitinib 5 mg and 10 mg BID groups) were reported to have had dose reductions due to AEs; 1 subject temporarily discontinued dosing (for a period of 3 days) due to herpes infection, which was recorded as a dose reduction. The second subject reduced the number of tablets (for a period of 8 days) from 2 tablets BID to 1 tablet daily due to vertigo, sickness, flatulence and diarrhea and missed the next dose of tablets (for a period of 3 days) due to recurrent symptoms. All events were considered mild and resolved, and the subjects subsequently resumed dosing at the original dose.

Overall, the most commonly reported AEs leading to temporary discontinuations were influenza and diarrhea, with the greatest number of temporary discontinuations in the tofacitinib 10 mg BID group. None of the AEs leading to temporary discontinuations were of severe intensity.

One subject in the tofacitinib 10 mg BID group experienced an SAE of pneumonia on Day 22, which resulted in temporary discontinuation. The event was reported as resolved on Day 30 and the subject resumed study treatment and completed the study.

Incidence of Clinical Laboratory Abnormalities and Change From Baseline in Clinical Laboratory Values Over 12 Weeks of Treatment

The incidence of laboratory test abnormalities is presented in Table 41. Mean Baseline and mean change from Baseline to last observation in laboratory parameters during the 12-week double-blind treatment is presented in Table 42.

Table 41. Incidence of Laboratory Test Abnormalities During the 12-Week Double-Blind Treatment - All Subjects

Group	Parameter	Unit	Criteria	Tofacitinib 5 mg BID (N = 327)	Tofacitinib 10 mg BID (N = 329)	Etanercept 50 mg BIW (N = 333)	Placebo (N = 105)
				n/N (%)	n/N (%)	n/N (%)	n/N (%)
Hematology	Hemoglobin (HGB)	g/dL	<0.8x LLN	1/326 (0.3)	1/329 (0.3)	0/333 (0.0)	0/105 (0.0)
	Hematocrit (HCT)	%	<0.8x LLN	1/326 (0.3)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Red blood cell count	10**6/mm**3	<0.8x LLN	1/326 (0.3)	1/329 (0.3)	0/333 (0.0)	0/105 (0.0)
	Reticulocytes (Abs)	10**3/mm**3	<0.5x LLN	0/326 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		10**3/mm**3	>1.5x ULN	0/326 (0.0)	0/329 (0.0)	2/333 (0.6)	0/105 (0.0)
	Mean corpuscular volume (MCV)	10**-15L	<0.9x LLN	1/326 (0.3)	1/329 (0.3)	0/333 (0.0)	0/105 (0.0)
		10**-15L	>1.1x ULN	4/326 (1.2)	7/329 (2.1)	6/333 (1.8)	2/105 (1.9)
	Mean corpuscular hemoglobin (MCH)	pg	<0.9x LLN	2/326 (0.6)	1/329 (0.3)	0/333 (0.0)	0/105 (0.0)
		pg	>1.1x ULN	1/326 (0.3)	0/329 (0.0)	1/333 (0.3)	0/105 (0.0)
	Mean corpuscular hemoglobin Concentration (MCHC)	g/dL	<0.9x LLN	0/326 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		g/dL	>1.1x ULN	0/326 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Platelet count	10**3/mm**3	<0.5x LLN	1/325 (0.3)	0/329 (0.0)	0/332 (0.0)	0/104 (0.0)
		10**3/mm**3	>1.75x ULN	0/325 (0.0)	0/329 (0.0)	0/332 (0.0)	0/104 (0.0)
	Reticulocytes	%	<0.5x LLN	0/326 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		%	>1.5x ULN	0/326 (0.0)	0/329 (0.0)	1/333 (0.3)	0/105 (0.0)
	White blood cell count	10**3/mm**3	<0.6x LLN	1/326 (0.3)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		10**3/mm**3	>1.5x ULN	2/326 (0.6)	0/329 (0.0)	0/333 (0.0)	1/105 (1.0)
	Lymphocyte count	10**3/mm**3	<0.8x LLN	15/326 (4.6)	7/329 (2.1)	6/333 (1.8)	2/105 (1.9)
		10**3/mm**3	>1.2x ULN	3/326 (0.9)	5/329 (1.5)	6/333 (1.8)	1/105 (1.0)
	Lymphocytes	%	<0.8x LLN	16/326 (4.9)	13/329 (4.0)	7/333 (2.1)	5/105 (4.8)
		%	>1.2x ULN	4/326 (1.2)	9/329 (2.7)	6/333 (1.8)	1/105 (1.0)
	Neutrophil count	10**3/mm**3	<0.8x LLN	11/326 (3.4)	9/329 (2.7)	16/333 (4.8)	2/105 (1.9)
		10**3/mm**3	>1.2x ULN	11/326 (3.4)	6/329 (1.8)	3/333 (0.9)	3/105 (2.9)
	Neutrophils	%	<0.8x LLN	6/326 (1.8)	2/329 (0.6)	10/333 (3.0)	1/105 (1.0)
		%	>1.2x ULN	0/326 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Basophil count	10**3/mm**3	>1.2x ULN	1/326 (0.3)	0/329 (0.0)	0/333 (0.0)	1/105 (1.0)
	Basophils	%	>1.2x ULN	2/326 (0.6)	0/329 (0.0)	0/333 (0.0)	1/105 (1.0)
	Eosinophil count	10**3/mm**3	>1.2x ULN	9/326 (2.8)	2/329 (0.6)	5/333 (1.5)	6/105 (5.7)
	Eosinophils	%	>1.2x ULN	14/326 (4.3)	8/329 (2.4)	21/333 (6.3)	12/105 (11.4)
	Monocyte count	10**3/mm**3	>1.2x ULN	8/326 (2.5)	2/329 (0.6)	5/333 (1.5)	1/105 (1.0)
	Monocytes	%	>1.2x ULN	5/326 (1.5)	5/329 (1.5)	7/333 (2.1)	0/105 (0.0)

Table 41. Incidence of Laboratory Test Abnormalities During the 12-Week Double-Blind Treatment - All Subjects

Group	Parameter	Unit	Criteria	Tofacitinib 5 mg BID (N = 327)	Tofacitinib 10 mg BID (N = 329)	Etanercept 50 mg BIW (N = 333)	Placebo (N = 105)
				n/N (%)	n/N (%)	n/N (%)	n/N (%)
Liver Function	Total bilirubin	mg/dL	>1.5x ULN	5/327 (1.5)	6/329 (1.8)	2/333 (0.6)	2/105 (1.9)
	Indirect bilirubin	mg/dL	>1.5x ULN	5/327 (1.5)	7/329 (2.1)	3/332 (0.9)	2/105 (1.9)
	Aspartate aminotransferase (AST)	IU/L	>3.0x ULN	0/327 (0.0)	1/329 (0.3)	1/333 (0.3)	0/105 (0.0)
	Alanine aminotransferase (ALT)	IU/L	>3.0x ULN	3/327 (0.9)	3/329 (0.9)	6/333 (1.8)	1/105 (1.0)
	Gamma glutamyl transferase (GGT)	IU/L	>3.0x ULN	11/327 (3.4)	9/329 (2.7)	10/333 (3.0)	0/105 (0.0)
	Lactate dehydrogenase (LDH)	IU/L	>3.0x ULN	0/326 (0.0)	0/329 (0.0)	0/332 (0.0)	0/105 (0.0)
	Alkaline phosphatase	IU/L	>3.0x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Total protein	g/dL	<0.8x LLN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		g/dL	>1.2x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Albumin	g/dL	<0.8x LLN	0/327 (0.0)	1/329 (0.3)	0/333 (0.0)	0/105 (0.0)
		g/dL	>1.2x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
Renal Function	Blood urea nitrogen (BUN) derived	mg/dL	>1.3x ULN	4/327 (1.2)	0/329 (0.0)	1/333 (0.3)	1/105 (1.0)
	Creatinine	mg/dL	>1.3x ULN	1/327 (0.3)	0/329 (0.0)	2/333 (0.6)	1/105 (1.0)
Lipids	Cholesterol	mg/dL	>1.3x ULN	58/327 (17.7)	63/329 (19.1)	31/333 (9.3)	4/105 (3.8)
	High density lipoprotein (HDL) cholesterol	mg/dL	<0.8x LLN	17/327 (5.2)	14/329 (4.3)	27/333 (8.1)	13/105 (12.4)
	Low density lipoprotein (LDL) derived	mg/dL	>1.2x ULN	94/326 (28.8)	91/326 (27.9)	61/331 (18.4)	11/104 (10.6)
	Triglycerides	mg/dL	>1.3x ULN	29/327 (8.9)	28/329 (8.5)	27/333 (8.1)	6/105 (5.7)
Electrolytes	Sodium	MEQ/L	<0.95x LLN	1/327 (0.3)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		MEQ/L	>1.05x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Potassium	MEQ/L	<0.9x LLN	1/327 (0.3)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		MEQ/L	>1.1x ULN	2/327 (0.6)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Chloride	MEQ/L	<0.9x LLN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
		MEQ/L	>1.1x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Calcium	MG/DL	<0.9x LLN	2/327 (0.6)	2/329 (0.6)	2/333 (0.6)	0/105 (0.0)
		MG/DL	>1.1x ULN	0/327 (0.0)	0/329 (0.0)	0/333 (0.0)	0/105 (0.0)
	Calcium Bicarbonate (venous)	MEQ/L	<0.9x LLN	12/327 (3.7)	17/329 (5.2)	15/333 (4.5)	5/105 (4.8)
		MEQ/L	>1.1x ULN	7/327 (2.1)	3/329 (0.9)	2/333 (0.6)	1/105 (1.0)
Clinical Chemistry (Other)	Glucose	mg/dL	<0.6x LLN	1/327 (0.3)	0/329 (0.0)	2/333 (0.6)	0/105 (0.0)
		mg/dL	>1.5x ULN	5/327 (1.5)	7/329 (2.1)	9/333 (2.7)	1/105 (1.0)
Immunology	C-reactive protein (CRP)	mg/dL	>1.25x ULN	95/327 (29.1)	71/329 (21.6)	79/333 (23.7)	59/105 (56.2)

Table 41. Incidence of Laboratory Test Abnormalities During the 12-Week Double-Blind Treatment - All Subjects

Group	Parameter	Unit	Criteria	Tofacitinib 5 mg BID (N = 327)	Tofacitinib 10 mg BID (N = 329)	Etanercept 50 mg BIW (N = 333)	Placebo (N = 105)
				n/N (%)	n/N (%)	n/N (%)	n/N (%)

N = number of subjects with any measurements during the 12-week study treatment.
n = number of subjects with any abnormality (specified criteria) measurements during the 12-week study treatment.
BID = twice daily, BIW = bi-weekly, LLN = lower limit of normal range, ULN = upper limit of normal range.

Table 42. Baseline and Change from Baseline to Last Observation During the 12-Week Double-Blind Treatment - Mean (Safety Population)

Parameter	Unit	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
			Mean			Mean			Mean			Mean	
		N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline
ALT	IU/L	327	36.3	0.9	329	36	2.5	333	35.7	3.9	105	35.3	-0.1
Albumin	g/dL	327	4.4	0.1	329	4.4	0.0	333	4.4	0.0	105	4.4	0.0
Alkaline phosphatase	IU/L	327	77.3	-8.6	329	72.8	-8.1	333	74.4	-6.8	105	79.4	-0.8
Apolipoprotein A1	mg/dL	322	141.3	12.9	322	145.4	12.5	329	142.1	5.1	103	137.7	1.3
Apolipoprotein B	mg/dL	322	96.2	6.4	322	97.2	4.2	329	98.6	-0.9	103	98.0	-1.5
AST	IU/L	327	28.7	0.9	329	28.7	1.9	333	29.1	0.7	105	28.7	-0.1
BUN derived	mg/dL	327	32.1	0.9	329	32.4	0.8	333	31.8	0.8	105	32.1	0.1
Basophils (%)	%	326	0.4	0.0	329	0.4	-0.1	333	0.4	0.0	105	0.4	0.0
Basophils (abs)	10**3/ mm**3	326	0.0	0.0	329	0.0	0.0	333	0.0	0.0	105	0.0	0.0
Bicarbonate (venous)	MEQ/L	326	25.2	-0.2	328	25.1	-0.1	332	25.3	-0.5	105	25.5	-0.3
C reactive protein	mg/dL	325	0.8	-0.5	325	0.7	-0.3	330	0.6	-0.3	105	0.9	-0.2
Calcium	mg/dL	327	9.7	0.0	329	9.7	0.0	333	9.8	0.0	105	9.8	-0.1
Chloride	MEQ/L	327	104	-0.2	329	103.7	0.0	333	103.8	0.0	105	104	-0.2
Cholesterol	mg/dL	327	191.9	10.3	329	194.5	11.6	333	193.5	1.4	105	192.7	-2.7
CK	U/L	327	122.3	47.8	329	121.3	59.0	333	140.7	-15.4	105	119.2	-10.6
Creatinine	mg/dL	327	1.2	0.0	329	1.2	0.0	333	1.2	0.0	105	1.1	0.0
Direct bilirubin	mg/dL	299	0.1	0.0	299	0.2	0.0	310	0.1	0.0	93	0.1	0.0
Eosinophils (%)	%	326	2.1	-0.3	329	2.1	-0.7	333	2.2	0.1	105	2.2	0.6
Eosinophils (abs)	10**3/ mm**3	326	0.2	0.0	329	0.2	-0.1	333	0.2	0.0	105	0.2	0.0
Erythrocytes distribution width	%	326	14.2	0.3	329	14.2	0.6	333	14.4	-0.1	105	14.3	0.1
GGT	IU/L	327	53.7	4.6	329	52.1	6.5	333	56.4	1.1	105	49	-0.1
Glucose	mg/dL	327	92.1	0.4	329	93.0	-0.1	333	91.9	1.9	105	93.7	0.8
Glycosylated Hemoglobin (HbA1c)	%	318	5.6	0.0	318	5.6	0.0	320	5.6	0.0	102	5.8	0.0
HDL cholesterol	mg/dL	327	50.3	4.1	329	52.0	5.9	333	49.7	0.9	105	48.6	-0.8
HCT	%	326	47.6	-0.5	329	47.9	-1.3	333	62.0	-14.0	105	46.9	0.5

Table 42. Baseline and Change from Baseline to Last Observation During the 12-Week Double-Blind Treatment - Mean (Safety Population)

Parameter	Unit	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
			Mean			Mean			Mean			Mean	
		N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline
HGB	g/dL	326	15.6	-0.1	329	15.8	-0.3	333	15.6	0.1	105	15.4	0.1
Indirect bilirubin	mg/dL	327	0.3	0.0	329	0.4	0.	332	0.3	0.0	105	0.3	0.0
LDH	IU/L	325	175.4	7.7	328	172.2	17.2	332	175.8	-11.8	105	179.9	-3.1
LDL derived	mg/dL	326	113.7	4.3	324	113.6	5.5	330	115.0	-2.0	103	112.9	0.2
Lymphocytes (%)	%	326	25.5	2.4	329	25.3	2.6	333	25.7	7.0	105	26.0	1.1
Lymphocytes (abs)	10**3/ mm**3	326	1.8	0.1	329	1.7	0.0	333	1.8	0.3	105	1.8	0.1
MCH	pg	326	31.2	0.1	329	31.2	0.3	333	31.2	0.0	105	31.3	-0.4
MCHC	g/dL	326	33.4	0.1	329	33.4	0.1	333	33.3	0.1	105	33.2	-0.2
MCV	10**-15 L	326	95.9	0.0	329	95.7	0.2	333	95.8	-0.1	105	96.1	-0.3
Monocytes (%)	%	326	5.9	0.3	329	5.9	0.4	333	5.9	0.6	105	5.9	0.1
Monocytes (abs)	10**3/ mm**3	326	0.4	0.0	329	0.4	0.0	333	0.4	0.0	105	0.4	0.0
Neutrophils (%)	%	326	65.9	-2.4	329	65.9	-2.2	333	65.4	-7.8	105	65.1	-1.9
Platelets	10**3/ mm**3	324	251.6	-10.4	329	243.6	-2.2	331	249.2	-18.2	104	254.2	-4.4
Potassium	MEQ/L	327	4.2	0.0	329	4.1	0.0	333	4.2	0.0	105	4.2	0.0
Red blood cell count	10**6/ mm**3	326	5.2	0.0	329	5.2	-0.1	333	5.2	0.0	105	5.1	0.1
Reticulocyte count (%)	%	326	1.5	0.1	329	1.4	0.2	333	1.5	0.0	105	1.5	-0.1
Reticulocytes (abs)	10**3/ mm**3	326	69.0	5.2	329	68.9	7.7	333	69.1	-0.4	105	68.5	-3.7
Sodium	MEQ/L	327	140.9	-0.1	329	140.7	0.0	333	140.8	-0.1	105	141	-0.1
Total bilirubin	mg/dL	327	0.6	0.1	329	0.6	0.0	333	0.5	0.	105	0.5	0.0
Total neutrophils (abs)	10**3/ mm**3	326	4.8	-0.4	329	4.7	-0.5	333	4.7	-0.9	105	4.9	-0.3
Total protein	g/dL	327	7.3	0.0	329	7.3	0.0	333	7.3	0.0	105	7.3	0.0
Triglycerides	mg/dL	327	80.8	7.1	329	84.4	1.0	333	81.8	7.3	105	90.8	-2.2
Urine specific gravity		327	1.0	3.1	328	1.0	3.1	333	4.1	0.0	105	1.0	0.0

Table 42. Baseline and Change from Baseline to Last Observation During the 12-Week Double-Blind Treatment - Mean (Safety Population)

Parameter	Unit	Tofacitinib 5 mg BID			Tofacitinib 10 mg BID			Etanercept 50 mg BIW			Placebo		
			Mean			Mean			Mean			Mean	
		N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline	N	Baseline	Change From Baseline
Urine pH		327	6.0	0.0	328	6.0	0.0	333	6.0	0.0	105	6.0	-0.1
White blood cell count	10**3/ mm**3	326	7.1	-0.3	329	7.1	-0.5	333	7.1	-0.6	105	7.3	-0.2

Baseline is defined as latest predose measurement.
Normalized data has been used in the computations.
ALT = alanine aminotransferase, AST = aspartate aminotransferase, BID = twice daily, BIW = bi-weekly, BUN = blood urea nitrogen, CK = creatine kinase, GGT = gamma glutamyl transferase, HCT = hematocrit, HDL = high density lipoprotein, HGB = hemoglobin, LDH = lactate dehydrogenase, LDL = low density lipoprotein, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, MCV = mean corpuscular volume, N = number of subjects with measurements.

Incidence of Clinically Significant Changes in Physical Examination From Baseline Over 12 Weeks of Treatment

Overall, values of weight were similar between all treatment groups and at all time points. Mean (standard error [SE]) change in weight from Baseline at Week 12 was 0.3 (0.3) kg for the tofacitinib 5 mg BID group, 1.1 (0.2) kg for the tofacitinib 10 mg BID group, 0.6 (0.1) kg for the etanercept 50 mg BIW group, and -0.4 (0.3) kg for the placebo group.

Incidence of Vital Sign (Blood Pressure and Heart Rate) Abnormalities and Change From Baseline in Vital Sign Measures Over 12 Weeks of Treatment

Descriptive statistics of actual and change from Baseline in systolic blood pressure (SBP, mmHg) and diastolic blood pressure (DBP, mmHg) during the 12-week double-blind treatment period are presented in Table 43 and Table 44.

Table 43. Descriptive Statistics of Systolic Blood Pressure (mmHg) Mean and Mean Change From Baseline During the 12-Week Double-Blind Treatment (Safety Population)

Visit	Treatment	N	Mean	SE	N	Mean Change	SE
Screening							
	Tofacitinib 5 mg BID	328	129.3	0.8			
	Tofacitinib 10 mg BID	328	128.9	0.9			
	Etanercept 50 mg BIW	335	129.3	1.0			
	Placebo	106	128.3	1.4			
Baseline							
	Tofacitinib 5 mg BID	329	127.7	0.8			
	Tofacitinib 10 mg BID	330	126.8	0.8			
	Etanercept 50 mg BIW	335	127.8	0.9			
	Placebo	107	127.6	1.4			
Week 2							
	Tofacitinib 5 mg BID	326	126.4	0.8	326	-1.4	0.6
	Tofacitinib 10 mg BID	325	126.6	0.8	325	-0.5	0.6
	Etanercept 50 mg BIW	330	127.6	0.9	330	-0.1	0.6
	Placebo	106	125.7	1.5	106	-1.9	1.1
Week 4							
	Tofacitinib 5 mg BID	319	126.5	0.8	319	-1.3	0.7
	Tofacitinib 10 mg BID	324	126.2	0.8	324	-0.7	0.6
	Etanercept 50 mg BIW	324	126.9	0.8	324	-0.8	0.6
	Placebo	103	124.8	1.4	103	-2.9	1.1
Week 8							
	Tofacitinib 5 mg BID	314	126.7	0.8	314	-1.2	0.7
	Tofacitinib 10 mg BID	320	125.5	0.8	320	-1.4	0.7
	Etanercept 50 mg BIW	323	126.8	0.8	323	-1.0	0.6
	Placebo	100	123.7	1.4	100	-4.1	1.2
Week 12							
	Tofacitinib 5 mg BID	312	127.4	0.8	312	-0.5	0.7
	Tofacitinib 10 mg BID	311	125.5	0.8	311	-1.4	0.7
	Etanercept 50 mg BIW	310	127.2	0.9	310	-0.4	0.7
	Placebo	95	124.2	1.6	95	-3.6	1.2

Any multiple-measurement BP within the same visit day, if any, were averaged prior to analysis.
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, BP = blood pressure, N = number of subjects, SE = standard error.

Table 44. Descriptive Statistics of Diastolic Blood Pressure (mmHg) Mean and Mean Change From Baseline During the 12-Week Double-Blind Treatment (Safety Population)

Visit	Treatment	N	Mean	SE	N	Mean Change	SE
Screening							
	Tofacitinib 5 mg BID	328	81.6	0.5			
	Tofacitinib 10 mg BID	328	81.1	0.6			
	Etanercept 50 mg BIW	335	80.7	0.6			
	Placebo	106	81.1	0.9			
Baseline							
	Tofacitinib 5 mg BID	329	81.0	0.5			
	Tofacitinib 10 mg BID	330	80.7	0.5			
	Etanercept 50 mg BIW	335	80.6	0.6			
	Placebo	107	79.7	0.9			
Week 2							
	Tofacitinib 5 mg BID	326	80.9	0.5	326	-0.3	0.4
	Tofacitinib 10 mg BID	325	79.9	0.5	325	-1.0	0.4
	Etanercept 50 mg BIW	330	80.3	0.5	330	-0.2	0.4
	Placebo	106	78.1	0.9	106	-1.6	0.8
Week 4							
	Tofacitinib 5 mg BID	319	80.2	0.5	319	-0.9	0.5
	Tofacitinib 10 mg BID	324	80.3	0.5	324	-0.5	0.5
	Etanercept 50 mg BIW	324	80.5	0.5	324	0.0	0.5
	Placebo	103	78.1	0.9	103	-1.4	0.8
Week 8							
	Tofacitinib 5 mg BID	314	80.6	0.5	314	-0.5	0.5
	Tofacitinib 10 mg BID	320	79.5	0.6	320	-1.2	0.5
	Etanercept 50 mg BIW	323	80.2	0.5	323	-0.3	0.5
	Placebo	100	78.2	0.8	100	-1.5	0.8
Week 12							
	Tofacitinib 5 mg BID	312	80.8	0.6	312	-0.2	0.5
	Tofacitinib 10 mg BID	311	79.5	0.5	311	-1.1	0.5
	Etanercept 50 mg BIW	310	80.3	0.5	310	-0.2	0.5
	Placebo	95	78.2	1.0	95	-1.4	0.9

Any multiple-measurement BP within the same visit day, if any, were averaged prior to analysis.
Baseline is defined as the last observation up to first dosing date.
BID = twice daily, BIW = twice weekly, BP = blood pressure, N = number of subjects, SE = standard error.

Incidence of Electrocardiogram Abnormalities and Change From Baseline in Electrocardiogram Measures Over 12 Weeks of Treatment

No clinically significant changes in ECG variables were observed at any time point or for any dose group, with no notable differences between treatment groups.

Change from baseline electrocardiogram results during the 12-week double-blind treatment period are summarized in Table 45.

Table 45. Descriptive Statistics of Change From Baseline Electrocardiogram Results During the 12-Week Double-Blind Treatment Safety Population

ECG	Visit	Treatment	N	Mean	SE
Heart Rate (beats/min)	Week 12	Tofacitinib 5 mg BID	300	-2.4	0.6
		Tofacitinib 10 mg BID	305	-1.7	0.5
		Etanercept 50 mg BIW	301	-0.4	0.6
		Placebo	94	-3.2	0.9
PR Interval (msec)	Week 12	Tofacitinib 5 mg BID	300	2.7	0.9
		Tofacitinib 10 mg BID	304	2.3	0.8
		Etanercept 50 mg BIW	298	3.1	0.7
		Placebo	94	0.0	1.3
QRS Complex (msec)	Week 12	Tofacitinib 5 mg BID	300	1.6	0.4
		Tofacitinib 10 mg BID	305	0.7	0.4
		Etanercept 50 mg BIW	301	0.3	0.4
		Placebo	94	0.1	0.8
QT Interval (msec)	Week 12	Tofacitinib 5 mg BID	300	4.9	1.4
		Tofacitinib 10 mg BID	305	2.1	1.3
		Etanercept 50 mg BIW	301	0.0	1.3
		Placebo	94	7.5	2.2
QTcB - Bazett's Correction Formula (msec)	Week 12	Tofacitinib 5 mg BID	300	-2.2	1.1
		Tofacitinib 10 mg BID	305	-2.8	1.1
		Etanercept 50 mg BIW	301	-0.6	1.2
		Placebo	94	-2.7	2.0
QTcF - Fridericia's Correction Formula (msec)	Week 12	Tofacitinib 5 mg BID	300	0.3	1.0
		Tofacitinib 10 mg BID	305	-1.0	0.9
		Etanercept 50 mg BIW	301	-0.3	1.0
		Placebo	94	0.8	1.7
RR Interval (msec)	Week 12	Tofacitinib 5 mg BID	300	31.4	7.5
		Tofacitinib 10 mg BID	305	20.7	6.2
		Etanercept 50 mg BIW	301	3.6	7.3
		Placebo	94	46.1	12.1

Multiple ECG measurements within the same visit day for each subject, if any, were averaged prior to summarizing across subjects.
BID = twice daily, BIW = twice weekly, ECG = electrocardiogram, N = number of subjects, SE = standard error.

Summary of Adjudicated Cardiovascular Endpoints

There were no fatal cardiovascular events.

The number of adjudicated cardiovascular endpoints (as determined by a prospective, independent, external adjudicated committee) was low, only 2 subjects had reported major adverse cardiovascular events (MACE): 1 (0.3%) subject in the tofacitinib 5 mg BID group (myocardial infarction [MI] with percutaneous coronary intervention/percutaneous transluminal coronary angioplasty) and 1 (0.3%) subject in the etanercept 50 mg BIW group (cerebrovascular accident).

Summary of Central Laboratory Pathologist Over-Read Malignancy Events

The overall incidence of subjects reporting malignancy events (including non-melanoma skin cancer [NMSC]) was low: 1 (0.3%) subjects in the tofacitinib 5 mg BID group; 2 (0.6%) subjects in the tofacitinib 10 mg BID group; and 2 (0.6%) subjects in the etanercept 50 mg BIW group. No lymphoma was observed.

One SAE of solid organ malignancy (gastric cancer) was reported in the tofacitinib 10 mg BID group on Day 42 of study treatment: The subject was a 58-year-old White male with a medical history of diffuse lung disorder and gastritis who had a history of alcohol abuse and was a smoker. He completed the 12-week study treatment period and, at the EOS Visit (Day 85), received omeprazole for mild epigastralgia. During enrollment in the extension study, symptoms worsened and an endoscopy and biopsy revealed gastric cancer. The subject died 8 months after completion of the current study (Day 315). The Investigator did not consider the event related to study treatment.

The remaining subjects with malignancy were reported to have NMSC, all of which were cases of basal cell carcinoma. Overall, the occurrence of NMSC was low and similar between the active treatment groups: 1 (0.3%) subjects in the tofacitinib 5 mg BID group; 1 (0.3%) subjects in the tofacitinib 10 mg BID group; and 2 (0.6%) subjects in the etanercept 50 mg BIW group. All subjects had a history of phototherapy (including PUVA and non-PUVA).

CONCLUSIONS:

- Tofacitinib 10 mg BID was non-inferior to etanercept 50 mg BIW and both tofacitinib 10 mg BID and etanercept 50 mg BIW were superior to placebo at Week 12 for both PASI75 and PGA “clear” or “almost clear” endpoints.

- Tofacitinib 5 mg BID did not meet the non-inferiority criterion as compared to etanercept 50 mg BIW.

- The PP analysis and other sensitivity analyses were consistent with the primary analyses.

- Median time to PASI75 response was shortest in the tofacitinib 10 mg BID group (approximately 9 weeks) as compared with approximately 12 weeks for tofacitinib 5 mg BID and etanercept 50 mg BIW groups.

- Median time to PGA "clear" or "almost clear" was approximately 8 weeks for tofacitinib 10 mg BID and etanercept 50 mg BIW and 12 weeks in the tofacitinib 5 mg BID group.

- At Week 12, PASI75 and PGA response rates were higher in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups versus the tofacitinib 5 mg BID group. All active treatment groups had a higher response rate compared to placebo. The percentage of subjects achieving a PASI90 response was small (<5%) for all active treatment groups at Week 2 and Week 4 but notably increased at Week 8 and Week 12. At Week 12, a similar percentage of subjects achieving a PASI90 response was observed in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups, with a smaller percentage of subjects in the tofacitinib 5 mg BID group. In comparison, only 1 (0.9%) subject in the placebo group achieved a PASI90 response.

- A substantial burden of disease at Baseline was observed with the PROs studied (ISI, DLQI, SF-36 PtGA, PQOL-12). For these PROs, statistically significant improvements were seen in all treatment groups versus placebo.

- Statistically significant and clinically meaningful improvement was observed at Week 12 for all treatment groups on the DLQI, with the greatest improvement seen with the tofacitinib 10 mg BID group and etanercept 50 mg BIW group.

- A statistically significant reduction in the ISI relative to placebo was seen for tofacitinib 5 mg and 10 mg BID groups as early as after 1 day of dosing (Study Day 2). Clinically significant reductions in the severity of itching were observed at Week 12, with the greatest effect in the tofacitinib 10 mg BID group.

- The most frequent system organ class AE categories were "infections and infestations" and "investigations."

- Six subjects (2 in each active treatment group) had serious infections: diverticulitis and extradural abscess in the tofacitinib 5 mg BID group, pneumonia and paronychia in the tofacitinib 10 mg BID group, and bronchitis and perineal abscess in the etanercept 50 mg BIW group.

- The incidence of herpes zoster events was 1 (0.3%) subject in the tofacitinib 5 mg BID group; and 2 (0.6%) subjects each in the tofacitinib 10 mg BID and etanercept 50 mg BIW groups.

- One SAE of solid organ malignancy (gastric cancer) was reported in the tofacitinib 10 mg BID group, which had a fatal outcome 8 months post-therapy.

- The remaining 4 malignancies were NMSC (all cases of basal cell carcinoma): 1 subject in the tofacitinib 5 mg BID group; 1 subject in the tofacitinib 10 mg BID group; and 2 subjects in the etanercept 50 mg BIW group.

- Adjudicated non-fatal major adverse cardiac events were reported for 2 subjects: 1 (0.3%) subject in the tofacitinib 5 mg BID group (MI with percutaneous coronary intervention/percutaneous transluminal coronary angioplasty) and 1 (0.3%) subject in the etanercept 50 mg BIW group (cerebrovascular accident).

- Two (1.9%) subjects in the placebo group experienced erythrodermic or guttate psoriasis (1 subject each, respectively). Both events were considered severe but not serious and both resolved.

- There was 1 diverticular perforation in a subject with acute diverticulitis in the tofacitinib 5 mg BID group.

- The majority of subjects (>98%) in all treatment groups had no abnormal liver function test (LFT) criteria at either Baseline or postdose. The overall incidence of abnormal LFT results was low for all treatment groups (<2%). One (0.3%) case of potential Hy's law was reported in the etanercept 50 mg BIW group postdose (at Week 12), which was attributed to an AE of choledocholithiasis. There were no confirmed cases meeting Hy's law criteria and no confirmed cases of drug-induced liver injury.